University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Masters Theses

Graduate School

5-2008

Regulation of Atp10c, a Novel Type 4 P-type ATPase, in 3T3-L1
Mouse Adipocytes
Amanda Lynn Peretich
University of Tennessee - Knoxville

Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes
Part of the Medicine and Health Sciences Commons

Recommended Citation
Peretich, Amanda Lynn, "Regulation of Atp10c, a Novel Type 4 P-type ATPase, in 3T3-L1 Mouse
Adipocytes. " Master's Thesis, University of Tennessee, 2008.
https://trace.tennessee.edu/utk_gradthes/426

This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and
Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE:
Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu.

To the Graduate Council:
I am submitting herewith a thesis written by Amanda Lynn Peretich entitled "Regulation of
Atp10c, a Novel Type 4 P-type ATPase, in 3T3-L1 Mouse Adipocytes." I have examined the final
electronic copy of this thesis for form and content and recommend that it be accepted in partial
fulfillment of the requirements for the degree of Master of Science, with a major in Comparative
and Experimental Medicine.
Madhu S. Dhar, Major Professor
We have read this thesis and recommend its acceptance:
Patricia K. Tithof, Roger C. Carroll
Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

To the Graduate Council:
I am submitting herewith a dissertation written by Amanda Lynn Peretich entitled
“Regulation of Atp10c, a Novel Type 4 P-type ATPase, in 3T3-L1 Mouse Adipocytes.” I
have examined the final electronic copy of this dissertation for form and content and
recommend that it be accepted in partial fulfillment of the requirements for the degree of
Master of Science, with a major in Comparative and Experimental Medicine.

Madhu S. Dhar
Major Professor

We have read this dissertation
and recommend its acceptance:
Patricia K. Tithof
Roger C. Carroll

Accepted for the Council:
Carolyn R. Hodges
Vice Provost and Dean of the
Graduate School

(Original signatures are on file with official student records.)

Regulation of Atp10c, a novel type 4 P-type
ATPase, in 3T3-L1 mouse adipocytes

A Thesis
Presented for the
Master of Science Degree
The University of Tennessee, Knoxville

Amanda Lynn Peretich
May 2008

DEDICATION
This thesis is dedicated

to my husband
the future Dr. Michael Peretich

to my parents and “the in-laws”
Mr. James “J.B.” Anderson II
Mrs. Jill Anderson
Mr. Edward Peretich
Mrs. Irene Peretich

to my siblings
James “Jamie” Anderson III
Brian Anderson
Mark Peretich
Melissa Peretich

to my best friends
James “Jamesway” the cat
Kylie “Chi-wee” the cat

ii

ACKNOWLEDGEMENTS
There are many people that deserve acknowledgement and thanks for their help
(known or unknown) in the completion of this thesis. First and foremost, I’d like to thank
my wonderful advisor, Dr. Madhu Dhar. During my time at the University of Tennessee
(UT), I came to know and respect her as both my mentor and my friend. As one of the
most dedicated, hard-working, balanced individuals I’ve ever had the privilege to work
with, she provided exceptional guidance and taught me invaluable life lessons for which I
will be eternally grateful. One of my professors during my undergraduate years at James
Madison University once told me that choosing your graduate advisor is one of the most
important decisions that you will ever make. I clearly made the best decision possible
with Madhu.
I would also like to acknowledge the assistance and intellectual conversations
from the other two members of my committee, Drs. Roger Carroll and Patricia Tithof.
Their willingness and dedication to the betterment of my graduate research experience
was greatly appreciated.
The Comparative and Experimental Medicine (CEM) graduate program at UT
provided me with this exceptional opportunity for a graduate education. Dr. Robert
“Buddy” Moore, Misty Bailey, Debbie Hampstead, and the rest of the staff in the CEM
program were extremely supportive and helpful during my time at UT. In addition to
support (educational and monetary) from the CEM program and the UTIA Center of
Excellence, I would also like to recognize support from Dr. Robert Holland and the Large
Animal Clinical Science department.

iii

During my two years at UT, I learned the benefit of collaborative efforts in the
advancement of research results. Ms. Nancy Neilsen provided extensive knowledge and
guidance in the cell culture techniques used throughout my research project. Members of
both Dr. Seung J. Baek and Dr. Howard Plummer’s laboratories demonstrated
compassion and cooperation, always willing to lend a reagent or some equipment. Both
Dr. Baek and Dr. Maria Cekanova helped formulate the research investigating the effect
of thiazolidinediones in this project. Dr. Guazhong Mao and Dr. Xuemin Xu provided
assistance with the proteins, and Dr. Kania’s laboratory allowed me to utilize and
dominate their centrifuge for days at a time.
Last, but certainly not least, I’d like to acknowledge my family and friends for
their love and support. It was extremely difficult to move away from everyone and
everything I had grown up to know in Virginia, but the friends I have made here helped
make that transition easier. As someone somewhere once said, “I get by with a little help
from my friends,” and I am extremely grateful for them. My family has also been
tremendously supportive and loving, even with all of the losses we have all been through
in the past few years. Always missing my angels in Heaven, I am able to carry on
because I know they are watching over me. Sometimes I wonder if I would have finished
this thesis without my wonderful husband, Michael. But with a love like ours, steadfast
and true, my best friend has been by my side through good times and bad. He has been
and will always be there for me, as will I for him.

iv

ABSTRACT
A recently identified phospholipid translocase, Atp10c, may be involved in the
modulation of glucose and lipid metabolism in mouse adipocytes. Aminophospholipid
translocases have previously been associated with cell signaling and intracellular protein
trafficking. In this study, the role of Atp10c in the insulin signaling pathway and
adipogenesis was investigated using the murine 3T3-L1 cell line.
Atp10c mRNA is highly expressed in undifferentiated cells and 2-fold downregulated during adipogenesis. Interestingly, Western blotting showed a band for
ATP10C protein at 70 kDa, a lower molecular weight than expected; ATP10C expression
increased during differentiation. Possible reasons for these discrepancies will be
discussed.
Since PPARgamma is considered to be the master regulator of adipogenesis and
controls the expression of adipocyte genes, the effect of PPARgamma agonists on Atp10c
expression was examined. The PPARgamma agonists and anti-diabetic drugs MCC555
and troglitazone both promoted adipogenesis and consequently reduced Atp10c
expression by 5-fold and 3-fold, respectively. When used in combination with the
PPARgamma antagonist GW9662, treatment rescued some of the decrease in Atp10c due
to MCC555 or troglitazone alone. The pattern of Atp10c expression is shown to be
opposite to that of PPARgamma.
Additionally, the correlation between effectors of glucose and lipid metabolism
and Atp10c was investigated. Treatment of 3T3-L1 adipocytes with insulin and
dexamethasone showed significantly increased expression of Atp10c; treatment with the
β-adrenergic factor isoproterenol slightly decreased expression. This suggests
v

transcriptional control of Atp10c by hormonal factors, but not β-adrenergic factors,
during differentiation.
To further explore the function of Atp10c in lipid metabolism, ATP10C silencing
through transient transfection of 3T3-L1 cells was first optimized to ultimately allow the
assessment of changes in proteins related to obesity and diabetes. An 84% and 77%
knockdown of Atp10c gene expression in preadipocytes and adipocytes, respectively, was
achieved. To elucidate a potential role for Atp10c/ATP10C in the insulin signaling
pathway, glucose uptake was investigated. Following Atp10c silencing in 3T3-L1
adipocytes, glucose uptake was significantly increased at both 24 and 48 hours.
Based on the results presented herein, the Atp10c gene and ATP10C protein have
an important role in the insulin signaling pathway and may be involved in adipogenesis.
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CHAPTER 1. INTRODUCTION
Obesity and diabetes are extremely prevalent in today’s society, with the numbers
continuing to rise each year [1-3]. With no recent research to indicate that these numbers
are going to decline in the future, obesity and diabetes remain a major public health
concern. New approaches must be undertaken to examine the correlation between the
two in order to elucidate unknown players in metabolic pathways related to obesity and
diabetes.
The novel type IV subfamily of P-type ATPases are putative aminophospholipid
translocases that have been associated with human disorders of intramembranous
transport [4, 5]. Studies in yeast have also shown that these flippases are important in
protein trafficking in the exocytic and endocytic pathways [6, 7]. Using positional
cloning and genomic sequencing strategies, the type IV P-type ATPase Atp10c has been
cloned to mouse chromosome 7 [8]. Heterozygous mice inheriting a maternal deletion of
the Atp10c gene exhibit typical hallmarks of insulin resistance syndrome including
obesity, hyperinsulinemia, and insulin resistance [9] and represent a novel genetic model
of diet-induced obesity and T2DM.
The precise biological role of these flippases in intracellular signaling and protein
trafficking are poorly understood, although there is a consensus on the physiological
function. The hypothesis of this project is that there is an association between type 4
ATPase mediated phospholipid translocase activities and cell signaling and intracellular
protein trafficking. To investigate the biological role of Atp10c/ATP10C in the process
of adipogenesis and the insulin signaling pathway, the Swiss murine 3T3-L1 cell line was
used as an in vitro model [10]. RT-PCR and Western blotting experimental techniques
1

were employed to monitor gene and protein expression. Following a basic
characterization of Atp10c/ATP10C, the effect of PPARγ agonists and effectors of
glucose and lipid metabolism on Atp10c expression was examined. Lastly, glucose
uptake was measured in adipocytes where Atp10c/ATP10C was knocked down with
siRNA in order to elucidate the possibility that Atp10c/ATP10C is involved in the insulin
signaling pathway.
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CHAPTER 2. LITERATURE REVIEW
Obesity and Type 2 Diabetes Mellitus (T2DM)
Obesity is a major public health concern that continues to affect more individuals
each year [1-3, 11-13]. Between 1980 and 2002, the prevalence of obesity doubled in
adults and the prevalence of overweight children and adolescents tripled [3, 14, 15]. The
most recent data from the 2003-2004 National Health and Nutrition Examination Survey
(NHANES) demonstrate that the number of overweight children and adolescents and
obese men has increased significantly from 1999 to 2004 in the United States [13].
Although there was no overall increase among women, the prevalence of obesity
remained constant at 33.2%. Similar rising trends are being observed throughout the
world [3, 16-19].
Obesity is a major risk factor for a number of common disorders, including noninsulin-dependent type 2 diabetes mellitus (T2DM) [20-22], atherosclerosis [23, 24], and
non-alcoholic fatty liver disease [25, 26]. T2DM is characterized by insulin resistance in
the muscle, fat, and liver, combined with a decreased ability of pancreatic β cells to
properly respond to elevated glucose levels. Increases in both obesity and diabetes
among adults in the United States continue in both sexes, all ages, all races, all
educational levels, and all smoking levels [2]. The prevalence of diabetes is also on the
rise throughout the world, with the projection that 366 million people will have diabetes
by 2030 [27].
There has been no recent research to indicate that these numbers are declining,
leaving the high levels of obesity and T2DM as a major public health concern. Based on
these increasing statistics, there is a dire need for new approaches to examine the
3

correlation between obesity and T2DM, to understand what causes these diseases, and to
elucidate unknown players in metabolic pathways related to obesity and T2DM. An
important link between obesity and T2DM is insulin resistance, the etiology of which is
complex in humans, with both genetic predisposition and environmental factors,
including nutritional and/or hormonal factors, playing an important role [28-31].
However, research searching for genes related to obesity and T2DM in humans has two
major pitfalls. First, the genetic influence on these diseases is based on multiple,
polymorphic single genes that each interact with other genes and may be exposed to
specific environmental factors. Second, if research focuses on the relation between a
single gene and obesity or T2DM while failing to control for other involved genes and
environmental exposures that have not been identified, then both experimental and
observational studies become difficult to interpret. Because these factors are difficult to
control in human subjects, polygenic diseases can be more easily studied in animal
models and then translated into human homologs and phenotypes.

Animal models of obesity and T2DM
Animal models have been used in research to investigate everything from drug
testing [32] to Huntington’s disease [33] to cancer [34] to obesity [35] to diabetes [36].
One of the common animal models used to study obesity and T2DM is the mouse model
[28, 35, 37-42], which can include spontaneous or artificially generated single-gene lossof-function mutation models [35].
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Spontaneous single-gene loss-of-function mutation mouse model
Spontaneous mutational events in large breeding establishments can lead to
genetic defects that have major loss-of-function effects in subsequent offspring.
However, the time between discovery of the defect and subsequent genetic and
physiological characterization may be delayed. For example, the ob/ob mouse was
discovered in 1950 when a spontaneous mutation led to obese mice [43], but
characterization of the gene did not reveal that the defect was a single base pair deletion
resulting in a premature stop codon for the leptin gene, which is highly expressed in
adipocytes, until 1994 [44].
Other spontaneous mutations have resulted in the discovery of Ay/Ay mice, which
have a deletion of the lethal yellow (Ay) gene and result in obese, diabetic mice with an
all-yellow coat [45]. The db/db mouse represents a model for diabetic dyslipidemia, with
a deletion of the diabetes (db) gene [46]. Additional spontaneous single-gene mutations
in fat and tubby (tub) have also been identified, leading to obese mice that exhibit
hyperglycemia, hyperinsulinemia, and elevated levels of total and HDL cholesterol [47,
48].
Although there are at least 10 single-gene loss-of-function mutations leading to
obesity that have been discovered and genetically characterized, genetic screens in
humans have indicated that very few individuals actually have a loss-of-function
mutation in any of these genes [49, 50]. The importance of these genes lies in further
understanding how the energy regulation system works and identifying other key players
of adipogenesis and the insulin signaling pathway [35].
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Artificially generated single-gene loss-of-function mutation mouse model
After witnessing spontaneous single-gene loss-of-function mutations, scientists
began to accelerate the process by increasing the mutation rate artificially through
exposure to mutagenic chemicals or radiation [8, 51]. These models can be used to look
at energy regulation as well as other aspects of animal function [35]. But this approach
can be costly in order to phenotype the mice, considering the mouse genome consists of
close to 40,000 genes. In addition, the effect of the gene deletion still must be visible in
the progeny. On the other hand, after these models are generated, they can be maintained
and used for further research purposes. One such mouse model is described in a later
section.
Transgenic mouse model
Single-gene mutations can also be artificially generated as a transgenic model,
where the mouse is genetically engineered to contain a transgene to cause overexpression
of, mutation in, or silencing of a target gene [42]. The first transgenic mouse was created
by Brinster et al in 1982 where the promoter region of the mouse metallothionein-I gene
fused to the herpesvirus thymidine kinase gene was injected into fertilized mouse eggs,
which were then transferred to a surrogate [52].
Transgenic mice can be generated not only to overexpress a certain gene [53-55],
but also to completely silence a gene. These “knockout” mice are created by complete
ablation of the target gene in all tissues to yield an associated phenotype [35]. For
example, silencing estrogen receptor-α in male and female mice leads to increased white
adipose tissue [56] whereas silencing the cannabinoid receptor CB1 leads to leanness and
resistance to diet-induced obesity [57].
6

These models can also sometimes lead to unexpected phenotypes, such as the axl
model that was originally generated to investigate the role of the tyrosine kinase receptor
axl in leukemia. Augustine et al found that constitutively expressing the axl gene
actually resulted in mice with T2DM [58].
Although expensive to generate, transgenic mouse models can be extremely
useful in scientific research to provide clues concerning the normal function of a specific
gene and how it may cause or contribute to a certain disease.
A novel polygenic mouse model
Mice containing radiation-induced chromosomal deletions on mouse chromosome
7 (MMU 7) located at the pink-eyed dilution (p) locus were generated and maintained at
Oak Ridge National Laboratory [59, 60]. The p-locus-associated obesity-1 (plo 1) region
of MMU 7 is associated with T2DM and maps to a region of quantitative trait loci
affecting body fat [8]. Using genetic mapping and phenotypic analyses, two distally
extending heterozygous deletions, p23DFiOD and p30PUb, were identified that encompass the
p locus on MMU 7 and cause diet-induced obesity and T2DM [59-61]. Heterozygous
mice inheriting either of the two p deletions maternally that were fed a high-fat diet
showed a significantly higher body weight, adiposity index, and plasma insulin, leptin,
and triglyceride concentrations compared to heterozygotes inheriting the deletion
paternally (Figure 1) [8].
Intraperitoneal glucose and insulin tolerance tests showed altered glucose
tolerance and insulin resistance after consumption of a high-fat diet for 4, 8, and 12
weeks. A 30% decrease in insulin-stimulated glucose uptake in white adipose tissue was
also seen after eating a high-fat diet for both 4 and 12 weeks, while a 35% decrease in the
7

Figure 1: Heterozygous mice inheriting a p deletion on MMU 7.
Mice inheriting the plo 1 locus maternally (right mouse) are significantly fatter than those
inheriting the same deletion paternally (left mouse). These mice are age- and sexmatched. Photo courtesy of E. Michaud, ORNL.
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soleus muscle was achieved only after 12 weeks [9]. Based on the above data, these p
deletion mutants represent a novel polygenic mouse model associated with obesity and
T2DM.

Atp10c
After the novel polygenic mouse model of obesity and T2DM described above
was generated, this phenotype was deletion-mapped to the plo 1 region, which
encompasses the 1 cM region between γ-aminobutyric acid A receptor β-3 (Gabrb3) and
ubiquitin protein ligase E3A (Ube3a) of MMU 7. Gabrb3 has been linked to cleft palate
formation in humans, while mutations in Ube3a cause the human neurological disorder
Angelman Syndrome [8]. This region is syntenic to the human chromosomal region HSA
15q11-q13 [62-65]. DNA sequencing showed that the only gene within this interval was
a P-type ATPase [8], which was later identified as Atp10c, or pfatp (Figure 2) [62, 66].
Atp10c is a novel type IV P-type ATPase and putative aminophospholipid
transporter (APLT) containing 21 exons. In p23DFiOD heterozygotes, the complete Ube3a
and the first two exons including the 5′ promoter region of Atp10c are deleted whereas
the complete Atp10c and Ube3a genes along with the 5′ and 3′ flanking regions are
deleted in p30PUb mice [66]. Since Ube3a transgenic mice are not obese [67, 68], it is
reasonable to expect that it is not the candidate for the altered glucose and lipid
metabolism disorders associated with the p locus deletions.
The sequence of the human ortholog, ATP10C, has been mapped to 15q12, which
is part of the critical region for Angelman Syndrome [62-64, 69]. Another deletion
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Figure 2: An integrated physical and deletion map of MMU 7.
This deletion map shows that Atp10c is the only transcript located in the region between
Gabrb3 and Ube3a on MMU 7. The solid black line in the middle is MMU 7 extending
from the centromeric (cen) to telomeric (tel) end. The arrows above the genes denote the
direction of transcription and the solid lines above the chromosome show the p deletions
generated. Modified from Dhar et al [66].
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mouse model has been reported that encompasses the same region as that of Atp10c,
which carries a transgene insertion that created a 4Mb deletion and represents a model of
Angelman Syndrome when maternally inherited [70]. The Angelman Syndrome mice are
viable and fertile but become obese at 4-6 months of age [70]. Cattanach et al also
reported a mouse model of Angelman Syndrome with late-onset obesity reported [71].
All of these models implicate Atp10c to be a strong candidate for the obesity phenotype.
Human geneticists have also identified a class of AS patients with the additional
phenotype of increased body mass index [72], suggesting that Atp10c/ATP10C may play
an important role in obesity of multiple etiologies, in mice and humans, respectively.
P-type ATPases
P-type adenosine triphosphatases (P-type ATPases) are the best known and most
extensively studied membrane transporters. Many of these integral membrane proteins
mediate the ATP-dependent transport of small cations across biological membranes by
the addition or removal of a high energy inorganic phosphate to or from an aspartate
residue in the conserved DKTGTLT amino acid sequence [73, 74].
Using phylogenetic analysis, P-type ATPases have been divided into five major
subfamilies [5]. The type I subfamily of P-type ATPases includes heavy metal ion
transporters, while the type II subfamily catalyzes transport of non-heavy metal ions,
such as the Na+K+-ATPase [73, 74]. The type III subfamily includes ATPases expressed
in plants and fungi that transport magnesium and hydrogen ions, while the type IV
subfamily members are found to transport phospholipids in eukaryotic cells. Although
only one member has been identified in the type V subfamily, this yeast ATPase has been
implicated in cellular calcium homeostasis and endoplasmic reticulum (ER) function [5].
11

Type IV P-type ATPases can be further subdivided into six different classes
based on sequence similarities [75]. Atp10c is part of class 1, which includes the
aminophospholipid translocases that are responsible for the asymmetric distribution of
membrane phospholipids [76]. Numerous type IV P-type ATPases have already been
associated with human disorders of intramembranous transport [4, 5], providing
additional evidence to look at the role of the novel type IV P-type ATPase Atp10c in
metabolic pathways.
Aminophospholipid transporters
The asymmetric phospholipid bilayer of a cell includes the choline-containing
phosphatidylcholine (PC) and sphingomyelin (SM) along with the aminophospholipids
phosphatidylserine (PS) and phosphatidylethanolamine (PE). PC and SM are localized in
the outer leaflet, while PS and PE are concentrated in the inner leaflet [6, 77-79]. This
asymmetry is essential to the mechanisms involved in normal cellular homeostasis and is
maintained by an energy-dependent translocation of aminophospholipids from the outer
to the inner leaflet catalyzed by aminophospholipid transporters (APLTs).
Randomization of phospholipids, which tend to equilibrate between the two leaflets, can
affect the structure and activity of channels, transporters, and signal transducing proteins.
In order to actively maintain the asymmetric phospholipid distribution, proteins that
translocate the phospholipids are necessary.
These lipid flippases, or lipid translocases, are a class of proteins involved in
regulation of phospholipid distribution in membrane bilayers [7]. Studies in yeast have
also shown that these flippases are important in protein trafficking in the exocytic and
endocytic pathways [6, 7]. Members of the type IV P-type ATPase subfamily are thought
12

to catalyze the transbilayer transport of amphipathic molecules, such as the
aminophospholipids PS and PE [79-81]. The founding member of this subfamily is the
yeast drs2 gene, which is an ortholog of mouse Atp10c that has been linked to ribosomal
assembly, formation of Golgi-coated vesicles, and maintenance of bilayer asymmetry
[82-84]. The murine Atp8a1 gene has also been recently investigated as a potential
aminophospholipid flippase; it was found to have properties similar to, but distinct from,
the properties of these flippases [85]. A deficiency of the human type IV P-type ATPase
ATP8B1 caused a loss of membrane asymmetry and reduced resistance to hydrophobic
bile salts. This loss of phospholipid asymmetry due to lack of a lipid flippase may
subsequently impair bile salt transport and cause cholestasis [86].
Translocase activity has been detected in a variety of membranes, including the
plasma membranes of erythrocytes, fibroblasts, spermatozoa, and the Golgi apparatus.
Changes in the physical properties of the lipid bilayers are suggested to alter several
functions such as cell-cell interaction, signal transduction pathways, and clotting
disorders by modulating the activity of lipid-dependent proteins. A loss of erythrocyte
PS asymmetry is seen in patients with diabetes or strokes [87-89], which emphasizes the
need to maintain the asymmetry of the lipid bilayer for normal cellular functions.
Changes in the composition of the lipid bilayer along with alterations in the asymmetry of
the adipocyte membranes result in obesity-related phenotypes. Studies have suggested
that SM, which accumulates in cell membranes in diseases with peroxisomal disorders,
may be involved with peroxisome proliferator-activated receptors (PPARs) and may also
contribute to insulin resistance [88, 89]. APLTs have a role(s) in insulin signaling,
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illustrating the importance of type IV P-type ATPases in cell biology and human health
and disease.

Insulin signaling pathway
Insulin is an important anabolic hormone that regulates a number of cell processes
with a strong, direct impact on cellular homeostasis. It increases the storage of
triglycerides in adipocytes via stimulation of lipogenesis (fat synthesis), inhibition of
lipolysis (fat breakdown), and differentiation of preadipocytes to adipocytes. The
resulting increase in adiposity causes secretion of various adipokines that can also lead to
secondary effects in liver and skeletal muscle. An abnormality in any of these processes
will result in insulin resistance, producing high levels of glucose and lipids in the blood.
Insulin resistance in skeletal muscle and adipose tissue can be caused by alterations in
insulin binding and signaling that effect glucose and lipid metabolism. In both tissues,
insulin sensitivity improves when insulin binds to its receptor, resulting in downstream
effects that lead to the uptake of glucose from the blood [90, 91].
A key rate-limiting step involved in an impaired insulin response is a defect in
glucose transport. Insulin stimulates glucose transport via translocation of an adipose
tissue- and muscle-specific glucose transporter protein, GLUT4, from the intracellular
space to the cell surface. Stimulation occurs when insulin binds to its heterotetrameric
integral membrane receptor, leading to activation of the tyrosine kinase domain of the
receptor. This triggers a signaling cascade that results in the translocation and fusion of
intracellular vesicles containing GLUT4 to the plasma membrane, which accounts for the
majority of glucose disposal in both muscle and adipose tissue (Figure 3) [92-95].
14

Figure 3: Insulin action in target tissues.
Insulin (i) binds to hetero-oligomeric insulin receptor (IR), stimulating
autophosphorylation of the receptor. This, in turn, leads to phosphorylation of the
docking proteins IRS1 and IRS2. IRS1 and IRS2 are coupled to the mitogen-activated
protein (MAP) kinase and phosphoinositide 3 (PI3) kinase signaling cascades. This leads
to translocation of vesicles containing the GLUT4 glucose transporter to the plasma
membrane, facilitating glucose (g) uptake by target tissues. Insulin signaling also
ultimately leads to changes in gene expression. Modified from Gannon [38].
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A major cause of insulin resistance in adipose tissue appears to be a depletion of GLUT4.
Conversely, GLUT4 levels are normal in the skeletal muscle. Thus, insulin resistance
seems to be caused by a defect in GLUT4 translocation. Abnormalities in glucose uptake
leading to insulin resistance can also arise from defects in insulin signal transduction
involving effector molecules in the pathway such as the insulin receptors IRS-1, IRS-2,
and IRS-3, and phosphoinositide 3-kinase (PI3K). Defects in any part of the insulin
signaling pathway have been shown to be important in the pathogenesis of insulin
resistance [92, 96, 97]. The question of how impaired glucose uptake and defective
insulin signaling in adipose tissue and skeletal muscle contributes to whole body insulin
resistance remains unanswered, but targeting insulin resistance has still become an
important therapeutic goal in the treatment of T2DM.

Fatty acid uptake
In addition to abnormalities in the insulin signaling pathway, a second aspect of
insulin resistance is its strong linkage with the regional distribution of adipose tissue.
Abdominal adipose tissue is more metabolically active than peripheral adipose tissue,
resulting in the release of more free fatty acids into the blood that are absorbed by the
liver and ultimately elevate glucose levels. In the peripheral tissues, elevated levels of
free fatty acids impair insulin secretion by the pancreas and result in increased insulin
resistance [98].
Fatty acids containing aliphatic tails with 16 or more carbons are known as longchain fatty acids and act as fuels to generate energy in the form of ATP. These fatty
acids are imported into adipocytes and transformed into triglycerides when bound to
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glycerol. The first step in the utilization of fatty acids is uptake across the plasma
membrane, which can occur either through diffusion or by protein mediation. Similar to
the uptake of glucose in the insulin signaling pathway, fatty acid uptake is also controlled
by insulin. A highly regulated process, fatty acid uptake mainly requires fatty acid
transport proteins (FATPs), which are also known as solute carrier family 27 (SLC27)
[99, 100]. Insulin induces an increase in fatty acid uptake by translocation of FATPs
from an intracellular compartment to the plasma membrane in adipocytes. There have
been six FATP genes identified in human and mouse genomes that each have special
physiological functions and specific tissue distribution [99-101]. Analyses of FATP1knockout mice have shown that insulin causes translocation of FATP1, which is
expressed in adipose tissue, skeletal muscle, and heart, and leads to enhanced fatty acid
uptake. However, the closely related FATP4 and CD36 proteins did not show a similar
localization, suggesting that FATP1 activity has an important role in cellular
homeostasis. FATP1 translocation has been suggested to involve a flip-flop or
translocase mechanism [102-104]. Stahl proposed a similar model for cellular fatty
uptake (Figure 4) in which long-chain fatty acids may be transported across the plasma
membrane directly by FATP complexes or first bind to CD36 proteins, which then
transfer the fatty acids on to FATPs [99]. Compared to research on GLUT4 trafficking
and the insulin signaling pathway, mechanisms underlying FATP1 trafficking in the
uptake of fatty acids are not clearly understood. However, there is some overlap between
these two pathways.
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Figure 4: A model for cellular fatty uptake.
Extracellular long-chain fatty acids (LCFA) may bind directly to fatty acid transport
protein (FATP) complexes to be transported into cells or they could bind to CD36 that
will then transfer the LCFA to a FATP dimmer. In order to prevent their efflux out of the
cell, intracellular LCFAs are coupled to coenzyme A (CoA) by long-chain fatty acyl-CoA
synthetase (LACS). Fatty acid binding proteins (FABPs) act as a cytoplasmic buffer.
Modified from Stahl [99].
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Adipogenesis
As described above, free fatty acids are imported into adipocytes and transformed
into lipid molecules. An increase in the number and/or size of these adipocytes leads to
obesity. The development of adipocytes, or adipogenesis, is an important process leading
to the deposition of fat that involves biochemical, physical, and molecular changes in the
conversion of undifferentiated to differentiated cells. This process is also largely
regulated by insulin, which exerts transcriptional and translational controls on adipogenic
factors.
The transition from an egg to the determination and conversion of preadipocytes
into mature adipocytes occurs in a series of stages in vivo (Figure 5). Adipogenesis is the
conversion of undifferentiated, fibroblast-like preadipocytes to mature, rounded
adipocytes following a phase of clonal expansion and subsequent growth arrest. Since fat
cell differentiation in vitro recapitulates most of the key features of adipogenesis in vivo,
cell culture techniques are extensively used to investigate this process [105].
Research aimed at identifying regulatory factors involved in adipocyte
differentiation has begun to provide important clues about adipocyte biology and its role
in the development of obesity and T2DM. Efforts to identify key inhibitors or activators
of adipogenesis assume that the potential to control or reverse this process might
ultimately lead to a way to inhibit the development of obesity and its associated
pathologies. Studies have shown that lipoprotein lipase is expressed early in the process,
followed by expression of C/EBPβ and C/EBPδ. Subsequently, the master regulators of
differentiation, C/EBPα and PPARγ, are expressed. Triglycerides also accumulate in the
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Figure 5: A model for the development of adipocytes.
Beginning with a fertilized egg, this shows a potential model for the development of
adipocytes based on the developmental stages of determination and commitment.
Darkened shapes represent nuclei or pronuclei. Modified from Ntambi and Kim [105].
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adipocytes and expression of fatty acid synthase, GLUT4, adipocyte binding protein 2,
and resistin increases [105-107].

PPARs and TZDs
Peroxisome proliferator-activated receptors (PPARs)
The nuclear receptor subfamily peroxisome proliferator-activated receptors
(PPARs) are transcription factors that bind to specific peroxisome proliferator response
elements (PPREs) in an enhancer site of a target gene upon binding of a ligand to the
PPAR [108, 109]. When an agonist binds to a PPAR, the conformation of PPAR is
altered and stabilized to allow recruitment of transcriptional coactivators and result in
increased gene transcription. Conversely, binding of an antagonist to PPAR will alter the
conformation to ultimately result in decreased gene transcription.
There are three isoforms that are each encoded by separate genes: PPARγ,
PPARα, and PPARδ. All of the PPARs are the primary targets of synthetic compounds
used to treat diabetes and dyslipidemia, while many of them also have putative roles in
other metabolic disorders [108, 109]. One of the more widely studied isoforms is
PPARγ, which is involved in both adipogenesis and the insulin signaling pathway.
PPARγ and adipogenesis
PPARγ is considered to be the master regulator of adipogenesis, controlling many
known and currently undiscovered aspects of the process. Differentiation is partly
regulated by a cascade of transcriptional events that lead to activation of CCAT/enhancer
binding proteins (C/EBPs) and PPARγ by insulin, dexamethasone, and
isobutylmethylxanthine that constitute the induction cocktail [110, 111]. Additional
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regulation of PPARγ activity during this process is a widely studied area with recent
studies showing a role for mitogen-activated protein kinase/extracellular regulated kinase
(MEK/ERK) signaling along with activation of C/EBPβ in the regulation of PPARγ
activity [110, 112]. Although intimately involved with fat cell differentiation, there is
still so much missing information concerning the role of PPARγ in this process that
constitutes the focus of many current research projects.
PPARγ and the insulin signaling pathway
In addition to its role in adipogenesis, PPARγ is involved in the insulin signaling
pathway. Liao et al recently demonstrated that suppression of PPARγ decreased insulinstimulated glucose uptake [113]. They also showed that PPARγ is essential for the
process of adipogenesis, but is not as necessary for the maintenance of an adipocyte state.
Although a PPARγ ligand with a high affinity, the novel modulator LG100641 does not
actually activate PPARγ; it blocks thiazolidinedione-induced PPARγ activation and
subsequent adipocyte differentiation [114]. Similar to other PPARγ ligands that do
activate PPARγ, LG100641 surprisingly increases glucose uptake in 3T3-L1 adipocytes.
The discovery of such PPARγ modulators that increase insulin sensitivity but do not
increase adipogenesis is important in the future of improved therapy for metabolic
diseases.
Thiazolidinediones (TZDs)
Thiazolidinediones (TZDs) are anti-diabetic drugs that enhance insulin sensitivity
and improve glucose uptake through the activation of PPARγ. Typically used in the
management of T2DM [115], TZDs have also been shown to exert anti-inflammatory
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effects on vascular cells [116]. Activation of PPARγ leads to increased adipogenesis,
thus treatment with TZDs should increase adiposity. Interestingly, TZDs actually inhibit
leptin (ob) gene expression, which is predominantly expressed in adipose cells, following
treatment of 3T3-L1 adipocytes [117]. These results suggest that the negative regulation
of leptin by TZDs may indicate that these compounds induce a state of adipocyte
differentiation that is subtly different from that induced by the differentiation cocktail.
There are numerous types of TZDs, although troglitazone (TGZ) and MCC555 will be
discussed here within.
Troglitazone (TGZ)
Troglitazone (TGZ), originally named CS-045 [118, 119], was the first member of
the TZD class of medications to be approved for clinical use [120, 121]. Previous
research indicated direct improvement of insulin action in liver, skeletal muscle, and
adipose tissue [118-120], along with the reduction of elevated plasma glucose in animal
models T2DM [119]. The marketed form of TGZ (Rezulin) was withdrawn in 2000 due
to increased hepatoxocitiy compared to the TZDs rosiglitazone (Avandia) and
pioglitazone (Actos) [122]. However, TGZ is still used in laboratory research today as a
representative TZD to investigate effects on PPARγ, adipogenesis, and/or the insulin
signaling pathway [123-125].
MCC555
MCC555, also known as RWJ-241947 [126], is a novel TZD that has been found
to have unique characteristics compared to the other TZDs [116, 127, 128]. Its effect on
the transcriptional activity of PPARγ depends on the cell type or DNA binding site; it can
act as a full agonist, partial agonist, or antagonist [129]. It is also the only TZD thus far
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that can activate PPARγ, PPARα, and PPARδ [116]. MCC555 not only exhibits antidiabetic effects, but also anti-proliferative activity against prostate cancer cells [126] and
anti-tumorigenic and/or pro-apoptotic activity in human colorectal cancer cells [130].
Mode of TZD action
It has been demonstrated that TZDs reduce insulin resistance in adipose tissue,
muscle, and the liver through a mechanism that involves activation of PPARγ [131].
However, PPARγ is predominantly expressed only in adipose tissue, not muscle or the
liver. This has led to investigations into a more exact mechanism of the action of TZDs.
Although the exact mode of the anti-diabetic action of TZDs drugs is still
unknown, there are two main hypotheses [131]. TZDs may cause PPARγ-mediated
actions on adipose tissue that indirectly trigger improved glucose homeostasis of skeletal
muscle and liver or they may improve insulin sensitivity by direct interaction with muscle
and liver in vivo (Figure 6). Further research is needed to elucidate an exact mechanism.

RNA interference
RNA interference (RNAi) is a post-transcriptional gene silencing that was first
coined in 1998 to describe the observation that double-stranded RNA could be used to
block gene expression [132]. It is initiated by a 21-23 nucleotide short interfering RNA
(siRNA) that is either generated in vitro by cleavage of double-stranded RNA using the
enzyme Dicer [133] or generated synthetically and introduced into the cell
experimentally (Figure 7). After the siRNA associates with the RNAi-induced silencing
complex (RISC), complementary mRNA transcripts are targeted for degradation. This
leads to silencing of the gene and, consequently, no new protein is translated.
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Figure 6: Possible modes of anti-diabetic TZD action.
It is known that TZD treatment activates PPARγ and leads to adipose tissue remodelling
along with the fact that insulin sensitization leads to improved glucose homeostasis.
However, the chain of events leading from TZD treatment to improved glucose
homeostasis is unknown. PPARγ activation and/or direct effects on adipose tissue may
be the sole cause of improved glucose homeostasis, or TZD treatment may directly
improve glucose homeostasis by direct interaction. Modified from Fursinn et al [131].
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Figure 7: RNAi pathway.
In order to form siRNA, long double-stranded RNA (dsRNA) is cleaved in vitro by the
Dicer enzyme in an ATP-dependent reaction or experimentally synthesized siRNA is
generated and transfected into the cells. The siRNA then forms a complex with the
RNAi-induced silencing complex (RISC). After the siRNA duplex is unwound with the
required ATP, the single-stranded antisense strand guides RISC to the messenger RNA
(mRNA). The complex binds to the strand at the complementary sequence, resulting in
cleavage of the target mRNA. Modified from Dykxhoorn et al [134].
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With the recent advent of synthetic siRNA technology, RNAi-based gene
silencing in cultured 3T3-L1 adipocytes has been extremely valuable in dissecting
elements crucial for the insulin signaling pathway and adipocyte differentiation [135137]. Gene silencing in cultured mammalian cells is being used as an effective way to
quickly screen if a specific gene is required for a biological function. It is also being used
in high throughput screens to determine if there are any genes within a large set of genes
required for a particular function [138]. The use of RNAi is definitely an important
experiment to do before more expensive experiments to generate transgenic mice are
undertaken.
RNAi has been used to examine the role of various genes and proteins in the
insulin signaling pathway. For example, knockdown of Golgin-160, a peripheral Golgi
protein known to be a caspase inhibitor during programmed cell death, actually led to
increased translocation of GLUT4 to the plasma membrane and the subsequent increase
in glucose uptake [139]. This suggests that Golgin-160 is required for the proper sorting
of GLUT4 to the insulin-responsive compartment for the uptake of glucose. On the other
hand, knockdown of the GTPase TC10α indicated that it is specifically required for
insulin-stimulated glucose uptake in adipocytes due to the inhibition of glucose uptake
and GLUT4 translocation upon silencing [140]. RNAi will be used in a similar fashion
for this project to study the role of Atp10c/ATP10C in the insulin signaling pathway.

Research project overview
Although there is a consensus on the physiological function of flippases in
intracellular signaling and protein trafficking, their precise biological roles are poorly
27

understood. The hypothesis of this project is that there is an association between type 4
ATPase mediated phospholipid translocase activities and cell signaling and intracellular
protein trafficking. The Swiss murine 3T3-L1 cell line [10] was used to investigate the
biological role of Atp10c/ATP10C in the process of adipogenesis and the insulin
signaling pathway. Specific experiments and the corresponding results will be discussed.
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CHAPTER 3. EXPERIMENTAL INVESTIGATIONS
Abstract
Previous research has shown that heterozygous mice inheriting a maternal
deletion of the Atp10c gene become obese and exhibit hyperinsulinemia, hyperlipidemia,
and hyperglycemia traditionally associated with T2DM [8, 66, 141]. Given the
complexity in the phenotype of these Atp10c heterozygous mice, it is difficult to
distinguish between primary and secondary effects in the whole animal model.
Therefore, the Swiss murine 3T3-L1 cell line [10] was used as an in vitro model and
primary preadipocytes isolated from mouse adipose tissue, plated, and differentiated in
culture were used as an ex vivo model to study the transcriptional and translational
regulation of Atp10c/ATP10C.
The aim of the present study was to investigate the biological role of
Atp10c/ATP10C in the process of adipogenesis and the insulin signaling pathway in the
in vitro model. Using RT-PCR to monitor gene expression and Western blotting to
monitor protein expression, Atp10c mRNA was 2-fold down-regulated while ATP10C
protein was up-regulated during adipogenesis. Treatment of adipocytes with a PPARγ
agonist further down-regulated Atp10c while increasing adipogenesis, suggesting a
potential role for Atp10c in the differentiation process and as a PPARγ modulator.
Glucose uptake in adipocytes was increased when Atp10c/ATP10C was knocked down
using siRNA, elucidating the possibility that Atp10c/ATP10C is involved in the insulin
signaling pathway. Based on these results, Atp10c/ATP10C has a role in the insulin
signaling pathway and may have a role in adipogenesis; further research is necessary to
confirm the exact function.
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Introduction
The prevalence of obesity and diabetes in society today continues to rise each
year [1-3]. In the United States, obesity increased from 19.8% to 20.9% while the
prevalence of diabetes increased from 7.3% to 7.9% from 2000 to 2001, respectively [2].
Similar rising trends are being observed throughout the world, with the projection that
366 million people will have diabetes by 2030 [27]. There has been no recent research to
indicate that these numbers are declining, leaving the high levels of obesity and T2DM as
a major public health concern. Based on these increasing statistics, there is a dire need
for new approaches to examine the correlation between obesity and T2DM, to understand
what causes these diseases, and to elucidate unknown players in metabolic pathways
related to obesity and T2DM.
The novel type IV subfamily of P-type ATPases are putative aminophospholipid
translocases that have been associated with human disorders of intramembranous
transport [4, 5]. Studies in yeast have also shown that these flippases are important in
protein trafficking in the exocytic and endocytic pathways [6, 7]. Using positional
cloning and genomic sequencing strategies, the novel type IV P-type ATPase Atp10c has
been cloned to mouse chromosome 7 [8]. Heterozygous mice inheriting a maternal
deletion of the Atp10c gene exhibit typical hallmarks of insulin resistance syndrome
including obesity, hyperinsulinemia, and insulin resistance [9]. These mice represent a
novel genetic model of diet-induced obesity and T2DM.
Although there is a consensus on the physiological function of these flippases in
intracellular signaling and protein trafficking, their precise biological roles are poorly
understood. The hypothesis of this project is that there is an association between type 4
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ATPase mediated phospholipid translocase activities and cell signaling and intracellular
protein trafficking. To investigate the biological role of Atp10c/ATP10C in the process
of adipogenesis and the insulin signaling pathway using the Swiss murine 3T3-L1 cell
line [10], reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting
were used to monitor gene and protein expression. A basic characterization of
Atp10c/ATP10C was performed, followed by examination of the effect of PPARγ
agonists and effectors of glucose and lipid metabolism on Atp10c expression. Lastly,
glucose uptake was measured in adipocytes where Atp10c/ATP10C was knocked down
with siRNA in order to elucidate the possibility that Atp10c/ATP10C is involved in the
insulin signaling pathway.

Materials and methods
More detailed, step-by-step instructions for many of the following methods are
located in the Appendix.
Materials
Cell culture reagents and oligonucleotides were obtained from Fisher Scientific
(Fairlawn, NJ). Insulin, isobutylmethylxanthine, isoproterenol, dexamethasone, and fetal
bovine serum were purchased from Sigma (St. Louis, MO). Thiazolidinediones MCC555
and troglitazone (TGZ) and the PPARγ inhibitor GW9662 were obtained from Cayman
(Ann Arbor, MI). Atp10c siRNA and HiPerfect transfection reagent was obtained from
Qiagen (Valencia, CA). DeliverX transfection reagent was purchased from Panomics,
Inc. (Fremont, CA).
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Animals
Mice containing the radiation-induced chromosomal deletion p23FiOD located at the
pink-eyed dilution (p) locus on MMU 7 were previously generated at Oak Ridge National
Laboratory [59, 60]. A homozygous deletion at the p locus is lethal, while heterozygous
mice will survive. The p23DFiOD strain contains a deletion of the first two of the 21 exons
of Atp10c, including the 5′ promoter region [9]. These mice are currently housed and
maintained at the University of Tennessee as previously described [61]. The wild-type
males are heavier than their age-matched female counterparts, thus only female mice are
currently being used for experimentation.
Previous research has shown that heterozygous mice fed a high-fat diet (45% fat)
maternally inheriting the Atp10c deletion exhibit a significantly higher body weight,
adiposity index, and plasma insulin, leptin, and triglyceride concentrations compared to
heterozygous mice that inherit the deletion paternally [9]. Therefore the mutant mice
inherit the deletion maternally, while the control mice inherit it paternally.
For the following methods, mice were fed a regular chow diet (Laboratory Rodent
Diet, Checkers PMI Nutritional International, Brentwood, MO) and killed by CO2
asphyxiation. Only control mice were used for this study. All procedures were approved
by and in accordance with the University of Tennessee Institutional Animal Care and Use
Committee (protocol #1309-1206).
Isolation and differentiation of primary preadipocytes and adipocytes
Preadipocytes and adipocytes were isolated from adipose tissue of 4−6 month old
adult female control mice [61] using the procedure of Rodbell with modifications [142].
Approximately 2 g of tissue was collected, minced into small pieces and digested with
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collagenase (2 g/L) (type I, Worthington Biochemical Corp., Lakewood, NJ) at 37°C for
25 min in modified Krebs-Ringer bicarbonate albumin buffer pH 7.4, containing 1 g/L
BSA and 4.4 mM glucose. Digested fat tissue was filtered through a 100 µm nylon mesh
and adipocytes were isolated by a low speed centrifugation at 800 rpm for 10 min. These
floating adipocytes were washed once with Hank’s balanced salt solution (HBSS) and
collected. The stromal vascular fraction rich in primary preadipocytes was then pelleted
by a high speed centrifugation at 1500 rpm for 15 min. Resulting stromal vascular
fraction cell pellets were treated with red blood cell lysis buffer (eBioscience, San Diego,
CA) for 5 min at room temperature, rinsed with phosphate buffered saline supplemented
with 1% BSA, and centrifuged at 800 rpm for 10 min. Stromal vascular fraction cells
were either collected or seeded in 6-well cell culture plates at a density of 5x105
cells/well.
At 70−80% confluency, primary preadipocytes in the stromal vascular fraction
cells were induced to differentiate in growth medium supplemented with 10 µg/ml insulin
(high insulin medium). Differentiation was complete in 8−10 days as assessed by Oil
Red O (ORO) staining and RT-PCR. These cells are the primary adipocytes obtained
from primary preadipocytes differentiated in culture.
3T3-L1 cell culture
3T3-L1 preadipocytes obtained from ATCC (Manassas, VA) were grown at 37ºC
in 5% CO2 in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum
and 1% penicillin/streptomycin (growth medium). At 70−80% confluency, adipocyte
differentiation was induced by incubating the cells in growth medium supplemented with
0.5 mM isobutylmethylxanthine, 1 µM dexamethasone, 1 µg/ml insulin, and 10 µM
33

troglitazone (differentiation medium) for two days. After 2 days, cells were maintained
in growth medium supplemented with 1 µg/ml insulin and 10 µM troglitazone
(maintenance medium) and grown for 7−10 days; the medium was changed every two to
three days. Cells were fully differentiated (>80%) by day 8−10 as assessed by ORO
staining and RT-PCR; these are 3T3-L1 adipocytes. Day 0 represents the day on which
the differentiation media is added.
Confluent 3T3-L1 preadipocytes or adipocytes were incubated for 24 hours in
serum-free medium before various effectors were added as described in the results.
PPARγ agonists and antagonists were replenished every time the media was changed.
Oil Red O staining
Differentiation was assessed using a modified procedure of ORO staining [143].
Cells were washed with HBSS and fixed with 1% paraformaldehyde for 5 min. Cells
were then rinsed with deionized water followed by the addition of two aliquots of 85%
propylene glycol for 5 min each. ORO stain was added (0.7% w/v in 85% propylene
glycol) and cells were gently swirled for 20 min at room temperature. Following a final
wash with 85% propylene glycol, cells were counterstained with hematoxylin. They
were visualized and photographed using a Zeiss Invertoskop 40C microscope and Canon
Powershot A620 digital camera.
ORO quantitation was performed using the procedure from the McNeil lab [144].
Briefly, cells were stained with ORO similar to above without the addition of
hematoxylin counterstain. After drying at RT for 10 min, ORO was eluted with the
addition of 100% isopropanol for 15 min, followed by OD measurement at 540 nm.
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Small interfering RNA (siRNA)
Two different Atp10c siRNAs were obtained (Qiagen, Valencia, CA); one was
generated from the sequence at the 3′ end of the Atp10c gene (sense: r(CCU GGG UAU
UGA AAC CAA A)dTdT and antisense: r(UUU GGU UUC AAU ACC CAG G) dTdG)
and the second was generated from the sequence at the 5′ end (sense: r(CGU CUU UGC
UGC AAU GAA A)dTdT and antisense: r(UUU CAU UGC AGC AAA GAC G)dGdA).
HiPerfect transfection reagent (Qiagen, Valencia, CA) was used to transfect
preadipocytes with 200 nM Atp10c siRNA while the lipid-based DeliverX transfection
reagent (Panomics, Fremont, CA) was used to transfect adipocytes with 30 nM Atp10c
siRNA. Preadipocytes or adipocytes were transfected with siRNA and either collected or
used for glucose uptake at 24 h, 48 h, or 72 h post-transfection. For experiments looking
at different days during adipogenesis, siRNA was added each time the media was
changed throughout differentiation. Beginning at day 6, siRNA was transfected using
both HiPerfect and DeliverX transfection reagents.
To transfect preadipocytes, equal volumes of 20 µM Atp10c siRNA and HiPerfect
transfection reagent were combined, flicked to mix, and left at room temperature for 10
min. Following incubation, 40 µl of the transfection complex was added to the medium
in each 60 mm cell culture dish.
Adipocytes were transfected as described [145]. Briefly, cells were washed once
with PBS and 300 µl of the 30 nM working siRNA transfection complex was added per
dish. Cells were incubated at room temperature for 3-5 min, followed by the addition of
300 µl serum-free media per dish and incubation under normal cell culture conditions for
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2-4 h. Finally, 1000 µl complete growth media was added per dish and incubated under
normal cell conditions for 24-72 h.
Semiquantitative RT-PCR
These procedures are as previously described, with modifications [141]. Total
RNA was extracted from 3T3-L1 preadipocytes and adipocytes, primary preadipocytes
and adipocytes fractionated from adipose tissue, and primary preadipocytes and
adipocytes plated and differentiated in culture using RNeasy Mini RNA kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. About 1x106 cells yield
30−50 µg of total RNA. Double-stranded cDNA was synthesized using the iScript
cDNA synthesis kit (Bio-Rad, Hercules, CA). Semi-quantitative RT-PCR was performed
for Atp10c (F-5’CCTGTGCTCTTCATTCTGGC3’, R5’CACTGCAGCTGTGAATCTGT3’), resistin (F5’ACTGAGTTGTGTCCTGCTAAG3’, R-5’CCACGCTCACTTCCCCGACATC3’),
and PPARγ (F-5’GGTGAAACTCTGGGAGATTC3’, R5’CAACCATTGGGTCAGCTCTT3’) mRNAs using GoTaq® Green Master Mix
(Promega Inc., Madison, WI) with β-actin (F-5’ATGGGTCAGAAGGACTCCTA3’, R5’CAACATAGCACAGCTTCTCT3’) as an internal control. RT-PCR was performed
under the following conditions: 5 min at 94°C followed by 30 cycles of denaturation at
94°C for 30 s, annealing at 54°C for 30 s, and extension at 72°C for 30 s, and finishing
with 5 min at 72°C. RT-PCR products were analyzed on 1% agarose gels containing 1
µg/µl ethidium bromide and viewed under ultraviolet light. Data are expressed as the
ratio of the target gene expression to that of an internal control.
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Protein preparations
Total membrane proteins
Total membrane proteins were isolated as described with modifications [146].
Briefly, cells were harvested and homogenized in homogenization buffer (20 mM
HEPES, pH 7.5 and 10 mM KCl), containing 1 mM protease inhibitors (pi), with a
PowerGen 700 polytron for 10 sec followed by passage through a 20-gauge needle 30
times. Following centrifugation, membrane pellets were resuspended in PARP buffer (50
mM tris, pH 6.8; 8 M urea; 2% SDS) with 1 mM DTT and 1 mM pi.
Whole cell lysates or total cellular extracts
Total proteins were isolated using two different methods: by SDS lysis buffer
[147] or by the standard radioimmunoprecipitation (RIPA) buffer.
Briefly, cells were washed twice with PBS at room temperature followed by the
addition of 1 ml lysis buffer at p 7.4 (4% SDS, 50 mM HEPES, 150 mM NaCl, 10 mM
DTT, 1:1000 pi). Cells were harvested with a cell scraper, transferred to a small
eppendorf tube, heated to 100°C for 5 min, and immediately stored at -80°C.
Total cell lysates were isolated using RIPA buffer according to the manufacturer’s
instructions (Boston Bioproducts, Inc., Worcester, MA). Briefly, cells were washed
twice with PBS on ice followed by the addition of 100 µl RIPA buffer supplemented with
pi (sodium orthovanadate, sodium fluoride, PMSF, aprotinin, leupeptin). Cells were
scraped, transferred to a small eppendorf tube, and stored at -80°C.
Subcellular proteins
Subcellular fractions of 3T3-L1 cells were isolated as follows [147]. Cells were
serum starved overnight at 37°C in DMEM supplemented with 1 mg/ml BSA. Then
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DMEM with or without 1 µM insulin was added and cells were incubated at 37°C for 30
min. Cells were washed once with HES buffer (250 mM sucrose, 20 mM HEPES, 1 mM
EDTA, pH 7.4) at room temperature. To each flask or dish, 3 ml HES supplemented with
1:1000 pi was added. Cells were scraped, collected in 50 ml Falcon tubes, and
homogenized for 10 sec with a PowerGen 700 Polytron followed by passage through a
20-gauge needle 30 times. The homogenate was transferred to a centrifuge tube; 300 µl
was collected as the whole cell lysate (WCL) fraction. Following centrifugation at 12000
rpm for 15 min at 4°C, the infranatant, which is comprised of the high density
microsomal (HDM), low density microsomal (LDM), and cytosolic fractions, was
collected in another centrifuge tube as the HLC fraction. The pellet was resuspended in
HES and homogenized with a 20-gauge needle 5 times followed by another
centrifugation at 12000 rpm for 20 min at 4°C. The supernatant was discarded and the
pellet was resuspended in HES again, followed by homogenization with a 20-guage
needle 5 times. This homogenate was overlaid on a 1.12 M sucrose cushion (29.78 g
sucrose in 100 ml HES) and centrifuged at 25000 rpm for 60 min at 4°C. The cloudy
interface was collected, resuspended in HES, and centrifuged at 18000 rpm for 30 min at
4°C. During centrifugation, the mitochondrial nuclear pellet from the previous run was
resuspended in 2 ml HES/pi and stored. After centrifugation, the plasma membrane
pellet was resuspended in 150 µl HES/pi and stored. The HLC fraction from earlier was
centrifuged at 20000 rpm for 30 min at 4°C. The supernatant was transferred to another
centrifuge tube and spun at 45000 rpm for 1.5 hr for 4°C. During centrifugation, the
HDM pellet was resuspended in 300 µl HES/pi and stored. Following centrifugation, the
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cytosolic supernatant was discarded and the LDM pellet was resuspended in 200 µl
HES/pi and stored.
Protein concentrations were determined using bicinchoninic acid (BCA) Protein
Assay Reagent (Pierce Biotech Inc., Rockford, IL).
Antibodies
Anti-mouse GLUT1 (Alpha Diagnostic International, San Antonio, TX), antirabbit GLUT 4 (Biogenesis, Mill Creek, WA, and Abcam, Cambridge, MA), anti-mouse
Na+/K+ ATPase (Novus Biologicals, Littleton, CO), anti-rabbit β–TUBULIN (Sigma
Genosys, St. Louis, MO), and anti-rabbit ATP10C (Sigma Genosys, St. Louis, MO)
antibodies were used for Western blot analysis. Anti-rabbit ATP10C was prepared and
affinity purified commercially against a 15 amino acid peptide (Sigma Genosys, St.
Louis, MO) followed by characterization using ELISA and peptide binding.
Western blot analysis
Western blotting was carried out according to standard procedures and as
previously described [148]. 20−100 µgs of proteins were resolved on 10% SDS-PAGE,
using 2X sample buffer containing β–mercaptoethanol as a reducing agent. Proteins
were transferred to nitrocellulose membranes and blocked for 1 h in blocking solution
(1% nonfat milk and 1% BSA in TBST buffer). Membranes were incubated with specific
primary antibodies overnight at 4ºC. Primary antibodies were detected with horseradish
peroxidase-coupled secondary antibody and antibody-protein complexes were detected
by Enhanced Chemiluminescence Western Blotting Detection Kit (Pierce Biotech Inc.,
Rockford, IL). Data from two independent experiments is reported. Results are
expressed as the ratio of target protein expression to that of an internal loading control.
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Glucose uptake
Glucose uptake in differentiated adipocytes was measured as previously described
[149]. Briefly, adipocytes were plated in 6-well cell culture plates at a density of 3x105
cells/well. Cells were washed with DMEM twice and serum starved in DMEM only for
3−5 hrs. Each 6-well plate was set-up such that wells 1, 2, and 3 did not contain insulin
and wells 4, 5, and 6 did contain insulin. Cells were stimulated with 100 µM insulin in
DMEM for 30 min at 37°C. The insulin induction was stopped by washing the cells
twice with 1 ml Krebs-Ringer HEPES (KRH) (121 mM NaCl, 4.9 mM KCl, 1.2 mM
MgSO4, 0.33 mM CaCl2, 12 mM HEPES) minus glucose at room temperature.
Cytochalasin B (5 µl of 1 mM stock/1 ml cocktail) was used to normalize for nonspecific glucose uptake. Glucose uptake was determined after the addition of 3H-2deoxyglucose (1 µl of 10 Ci/mmol stock/1 ml cocktail) in KRH buffer at 37°C for 5 min.
Incorporation was terminated by washing the cells twice with 1ml ice cold KRH plus
glucose (25 mM glucose). Cells were lysed at room temperature for 5 min with 2.2 ml
digitonin release buffer (0.25 M mannitol, 17 mM MOPS, 2.5 mM EDTA, 0.25 M
digitonin). Following incubation, 2 ml of the cell lysates were mixed with 10 ml
scintillation fluid and counted. 200 µl of the lysate was stored at -80°C for protein
quantitation.
Statistical analysis
Semiquantitative RT-PCR products on the agarose gels and protein bands on the
Western blots were quantitated using Scion Imaging Software
(http://www.scioncorp.com). Results are shown as means + SD. Mean comparisons
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were tested by two-tailed unpaired Student’s t-test with P values <0.01 considered highly
significant and <0.05 considered significant.

Results
Atp10c mRNA is expressed in 3T3-L1 cells
In order to use 3T3-L1 cells as an in vitro system to study the regulation of the
novel gene Atp10c, its presence was first demonstrated in these cells. Using RT-PCR, an
886 bp product was detected in both the undifferentiated and differentiated 3T3-L1 cells
(Figure 8). This product has been demonstrated and confirmed to be a part of Atp10c
cDNA (Dhar 2004). Quantitative analysis showed that Atp10c is 2-fold down-regulated
in 3T3-L1 adipocytes after differentiation using β-actin as the control. As expected,
PPARγ and resistin were up-regulated, serving as internal positive controls.
Atp10c mRNA is expressed in primary preadipocytes and adipocytes
To investigate whether the pattern of expression of Atp10c mRNA in vitro is
comparable to that ex vivo and determine if a significant decrease in Atp10c expression is
indeed related to the adipogenesis process, Atp10c mRNA was next quantitated in
purified primary preadipocytes and adipocytes from mouse adipose tissue and in primary
preadipocytes differentiated in culture. Atp10c was expressed in all of these types of
cells (Figure 9). Compared to primary preadipocytes from mouse adipose tissue, Atp10c
mRNA was significantly down-regulated in primary adipocytes from mouse adipose
tissue, again confirming the regulation of Atp10c expression during adipogenesis (Figure
9A).
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Figure 8: Atp10c mRNA is expressed in 3T3-L1 cells.
Atp10c, resistin, and PPARγ expression was examined by RT-PCR in 3T3-L1
preadipocytes (PA) and adipocytes (Ad); β-actin served as an internal control. Numbers
in parentheses denote PCR product size in base pairs (bp).
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Figure 9: Atp10c mRNA is expressed in primary preadipocytes and adipocytes.
RT-PCR analysis was used to determine Atp10c, resistin, and PPARγ expression in
primary preadipocytes (PA) and adipocytes (Ad); β-actin served as an internal control.
Expression is shown in primary preadipocytes and primary adipocytes purified from
mouse adipose tissue (A) or harvested from culture (B). ORO staining (C) was used to
monitor and confirm differentiation of primary preadipocytes in culture. Numbers in
parentheses denote PCR product size in base pairs (bp).
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Adipose tissue is comprised of several types of cells such as fibroblasts, nondifferentiated mesenchymal cells, preadipocytes, and adipocytes. Adipocytes develop
from fibroblast-like preadipocytes within the stromal vascular fraction [150, 151]. To
ensure that stromal vascular fraction cells in the preparations were comprised mainly of
preadipocytes and that Atp10c expression was specific to the preadipocyte fraction,
stromal vascular fraction cells were plated in cell culture dishes and differentiated to
adipocytes. Atp10c expression was then measured and, interestingly, was 2-fold upregulated when primary preadipocytes were differentiated to adipocytes in culture (Figure
9B). ORO staining was used to monitor differentiation in culture and to confirm that the
harvested cells showed >80% differentiation (Figure 9C). This increase in Atp10c
expression may be due to high insulin present in the differentiation and maintenance
media used for primary cultures.
Due to the fact that Atp10c is similarly regulated both in vitro and ex vivo, and
3T3-L1 cells are widely used as models of adipogenesis, most experiments were carried
out mainly in 3T3-L1 cells.
ATP10C protein is expressed in 3T3-L1 cells
After demonstrating the expression of Atp10c at the mRNA level, the next step
was to investigate the expression of ATP10C protein. Based on the amino acid sequence
of ATP10C, the expected molecular weight of the protein is 169 kDa. At first, there were
no bands present in that range on the protein blots. This led to an experiment looking at
different sample loading buffers with or without the addition of a reducing agent (Figure
10). The original sample loading buffer used from New England BioLabs (NEB) without
DTT did not have any bands present in the 169 kDa range and very faint bands in the 70
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Figure 10: Different sample loading buffers can be used for Western blots.
Equal amounts of preadipocyte (PA) and adipocyte (Ad) whole cell lysate proteins were
loaded on a Western gel using four sample loading buffers: general, NEB + DTT,
Laemmli, and Upstate (which contained β-mercaptoethanol). The membranes were
probed with ATP10C antibody.
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kDa range. The other sample loading buffers tested included a general buffer [152], NEB
with DTT [153], Laemmli [154], and Upstate [155]. After switching to Upstate sample
loading buffer, distinct bands were apparent in an upper range close to 140 kDa and a
lower range at 70 kDa.
To confirm that the upper band was indeed ATP10C, a peptide neutralization
experiment was performed. In this experiment, a neutralizing (or blocking) peptide
consisting of the 15 amino acids used to generate the ATP10C antibody was added in 10fold excess to the ATP10C antibody. This neutralizing peptide competed with the
ATP10C antibody to block binding of the antibody to the antigen. After developing the
Western blot, the addition of the neutralizing peptide will compete out the ATP10C
protein band. Surprisingly, this experiment showed that the ATP10C protein band that
was competed out is 70 kDa (Figure 11). Therefore, this lower molecular weight
ATP10C band was the focus for future experiments.
Since Atp10c mRNA showed a 2-fold decrease during adipogenesis, expression of
ATP10C protein was monitored to see if a similar pattern existed. Interestingly, ATP10C
protein actually increased throughout differentiation of preadipocytes to adipocytes, with
β-TUBULIN serving as the control (Figure 12).
Atp10c mRNA expression is regulated by PPARγ agonists and antagonists
Since PPARγ is considered to be the master regulator of adipogenesis [110] and
controls the expression of adipocyte genes, the effect of PPARγ agonists on Atp10c
expression was investigated to assess whether Atp10c expression is also under PPARγ
control. Two anti-diabetic drugs that activate PPARγ and thus promote adipogenesis,
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Figure 11: Peptide neutralization shows an ATP10C protein band at 70kDa.
Equal amounts of preadipocyte (PA) and adipocyte (Ad) whole cell lysate proteins were
loaded on a Western gel and probed in the absence (A) or presence (B) of 10-fold excess
neutralizing peptide with ATP10C antibody.
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Figure 12: ATP10C protein expression increases throughout differentiation.
ATP10C expression was examined by Western blotting using 3T3-L1 total proteins
collected in SDS lysis buffer at days 0, 3, 4, 6, 7, and 9 post-induction; β-TUBULIN
served as an internal control. The expression of ATP10C is denoted as arbitrary units
(A.U.) and represented as the fold change normalized to β-TUBULIN. **P<0.01.
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MCC555 and troglitazone (TGZ), were used [109, 130]. Confluent preadipocytes were
maintained in serum-free media supplemented with 10 µM TGZ or 10 µM MCC555 and
harvested after 24 h. 3T3-L1 adipocytes were also treated with the same reagents
throughout differentiation and harvested. Atp10c mRNA expression was quantitated in
both cell types. As demonstrated by RT-PCR and ORO staining, both MCC555 and TGZ
promoted adipogenesis and consequently reduced Atp10c expression by 5-fold and 3-fold
respectively (Figure 13). This significant decrease in adipocytes confirmed not only that
Atp10c expression was reduced in differentiated cells, but also that these PPARγ agonists
further down-regulate its expression.
To clarify and confirm that the decrease in Atp10c was indeed due to the process
of adipogenesis controlled by PPARγ, Atp10c expression was also assessed in cells
treated with a PPARγ antagonist, GW9662 [156]. Atp10c expression in adipocytes
treated with GW9662 alone did not decrease and was similar to that in control cells
treated with the vehicle DMSO (Figure 13). However, when GW9662 was added to the
cells along with MCC555 or TGZ, there was only a 2-fold or a 4-fold decrease in Atp10c
expression, respectively. This suggests that GW9662 inhibited adipogenesis and rescued
some of the decrease in Atp10c expression due to MCC555 or TGZ alone.
Atp10c and PPARγ mRNAs are oppositely regulated in 3T3-L1 cells during
adipogenesis
Both MCC555 and TGZ are PPARγ agonists that decrease Atp10c expression
along with anti-diabetic drugs that are members of the thiazolidinedione class. Due to the
fact that TGZ was withdrawn from the market because of adverse side effects while
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Figure 13: Atp10c mRNA expression is regulated by PPARγ agonists and
antagonists.
RT-PCR analysis shows Atp10c expression in 3T3-L1 adipocytes harvested between days
8−10 of differentiation. MCC555, troglitazone (TGZ), and GW9662 were added to the
media throughout the differentiation process and replenished whenever the media was
changed. Expression of Atp10c mRNA in adipocytes treated with DMSO (CONTROL),
MCC555, TGZ, and/or GW9662 is shown, with β-actin serving as an internal control.
The expression of Atp10c is denoted as arbitrary units (A.U.) and represented as the fold
change normalized to β-actin. ORO staining was used to monitor morphological changes
in adipocytes in the presence of PPARγ agonists and antagonists. *P<0.05, ***P<0.001.
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MCC555 is a newer experimental drug, the following experiments examined the effect of
MCC555 only.
Atp10c expression was compared to that of PPARγ in cells treated with MCC555,
GW9662, a combination of MCC555 and GW9662. Cells were harvested at days 3, 4, 5,
and 9 post-induction to gain further insight into the transcriptional control of Atp10c
during adipogenesis (Figure 14). In the control cells, high levels of Atp10c were
expressed at day 3 that gradually decreased through days 4−9 (Figure 14A). When >80%
of preadipocytes were differentiated into adipocytes at day 9, Atp10c expression was 2fold down-regulated, supporting the earlier results. Cells treated with the PPARγ agonist
and/or antagonist showed a similar pattern of decreased Atp10c expression. However,
treatment with MCC555 showed even lower Atp10c levels throughout differentiation
compared to control cells; some of this decrease was rescued by the combination of
GW9662 with MCC555, confirming the earlier results. As expected, PPARγ expression
increased significantly through days 3−9 (Figure 14B). ORO staining was carried out to
monitor the differentiation process (Figure 15); quantitation confirms increased
adipogenesis of cells treated with MCC555 compared to control cells treated with DMSO
(Figure 16).
Atp10c mRNA is regulated by hormonal inducers
Since Atp10c was expressed and levels were modulated during the differentiation
of 3T3-L1 preadipocytes to adipocytes, the regulation of Atp10c mRNA expression by
effector molecules of glucose and fat metabolism in undifferentiated and differentiated
cells was investigated. This was examined by incubating cells with 100 nM insulin, 100
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Figure 14: Atp10c and PPARγ  mRNAs are oppositely regulated in 3T3-L1 cells
during adipogenesis.
RT-PCR analysis was used to determine Atp10c (A) and PPARγ (B) mRNA expression in
3T3-L1 cells at days 3, 4, 6, and 9 post-induction; β-actin served as an internal control.
Cells were treated throughout differentiation with the vehicle DMSO, MCC555, and/or
GW9662. Expression of Atp10c and PPARγ mRNA is denoted as arbitrary units (A.U.)
and represented as the fold change normalized to β-actin. *P<0.05, **P<0.01,
***P<0.001.
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Figure 15: ORO staining shows morphological changes during adipogenesis in 3T3L1 cells following treatment with PPARγ agonists and antagonists.
ORO staining was used to assess the morphological changes in 3T3-L1 cells at days 3, 4,
6, and 9 post-induction. Cells were treated throughout differentiation with the vehicle
DMSO, MCC555, or a combination of MCC555 and GW9662.
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Figure 16: ORO quantitation confirms adipogenesis in 3T3-L1 cells following
treatment with PPARγ agonists and antagonists.
ORO quantitation was used to determine the extent of adipose conversion in 3T3-L1 cells
at days 3, 4, 6, and 9 post-induction. Cells were treated throughout differentiation with
the vehicle DMSO, MCC555, and/or GW9662. On the specified days, cells were treated
with ORO, which stains only the fat cells. The total ORO stain taken up by the cells was
eluted with 100% isopropanol and the OD measured at 540 nm. Expression of ORO is
denoted as arbitrary units (A.U.) and represented as the fold change of the PPARγ agonist
or antagonist normalized to DMSO. *P<0.05, **P<0.01.
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nM dexamethasone, or 100 nM isoproterenol for 24 h. Atp10c mRNA increased 4-fold or
6-fold, respectively, when insulin or dexamethasone was added to 3T3-L1 adipocytes
(Figure 17A); there was no significant change in preadipocytes. As expected, resistin
mRNA decreased following treatment with insulin or dexamethasone (Figure 17B).
Atp10c mRNA expression slightly decreased after incubating the cells with 100
nM isoproterenol, but this was not statistically significant (data not shown). The
regulation of Atp10c mRNA expression by 100 nM insulin or 100 nM dexamethasone
was also investigated in primary preadipocytes differentiated in culture. Atp10c mRNA
slightly increased 1.5-fold or 1.4-fold, respectively, when insulin or dexamethasone was
added to differentiated primary adipocytes (Figure 18). Based on these results, the upregulation of Atp10c observed in primary adipocytes differentiated in culture (Figure 9B)
was most likely due to the high insulin that is used in the differentiation media, which is
10-fold higher than this treatment with insulin.
Atp10c mRNA and protein are knocked down in 3T3-L1 preadipocytes using
siRNA
Small interfering RNA (siRNA) can be used to knockdown the expression of a
specific target gene and protein for further studies. Using two synthetic siRNAs, the
knockdown of Atp10c mRNA was standardized in 3T3-L1 preadipocytes at different time
points (Figure 19). Transient transfection with 200 nM of 5′ Atp10c siRNA using
HiPerfect transfection reagent showed the most consistent decrease in Atp10c expression,
with 87%, 80%, and 93% knockdown at 24, 48, and 72 h, respectively. Transfection of
3T3-L1 preadipocytes also showed knockdown at the protein level, with 25% and 28%
decrease in Atp10c expression at 48 and 72 h, respectively (Figure 20).
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Figure 17: Atp10c mRNA expression is regulated conversely to that of resistin
mRNA in 3T3-L1 adipocytes following treatment with hormonal factors.
RT-PCR analysis was used to determine Atp10c (A) and resistin (B) mRNA expression
in untreated 3T3-L1 adipocytes (CON), and following treatment with 100 nM insulin
(INS) or 100 nM dexamethasone (DEX) for 24 h. β-actin is used as an internal control.
Expression of Atp10c and resistin mRNA is denoted as arbitrary units (A.U.) and
represented as the fold change normalized to β-actin. ***P<0.001.
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Figure 18: Atp10c mRNA expression is regulated in primary adipocytes following
treatment with hormonal factors.
RT-PCR analysis was used to determine Atp10c mRNA expression in primary adipocytes
differentiated in culture from control mice. Primary adipocytes were untreated (CON), or
treated with 100 nM insulin (INS) or 100 nM dexamethasone (DEX) for 24 hours. βactin is used as an internal control. Expression of Atp10c mRNA is denoted as arbitrary
units (A.U.) and represented as the fold change normalized to β-actin. *P<0.05.
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Figure 19: Standardization of Atp10c mRNA knockdown in 3T3-L1 preadipocytes
using siRNA.
RT-PCR analysis was used to determine Atp10c mRNA expression in 3T3-L1
preadipocytes treated with 100 nM, 200 nM, 300 nM, 400 nM, or 500 nM of 5′ or 3′
Atp10c siRNA for 24, 48, or 72 h. β-actin is used as an internal control. Not all
concentrations or times were tested (indicated by ζ). Expression of Atp10c mRNA is
denoted as arbitrary units (A.U.) and represented as the fold change normalized to βactin.
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Figure 20: ATP10C protein is knocked down in 3T3-L1 preadipocytes using siRNA.
Western blotting was used to determine ATP10C protein expression in 3T3-L1
preadipocytes treated with 200 nM of 5′ ATP10C siRNA for 24, 48, or 72 h; βTUBULIN is used as an internal control. Expression of ATP10C is denoted as arbitrary
units (A.U.) and represented as the fold change normalized to β-TUBULIN.
***P<0.001.
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Atp10c mRNA and protein are knocked down in 3T3-L1 adipocytes using siRNA
After determining that siRNA could be used to knockdown Atp10c/ATP10C
expression in 3T3-L1 preadipocytes, the effect of siRNA in adipocytes was investigated.
Adipocytes are generally more difficult to transfect than preadipocytes, however the
novel “MPG” delivery technology (Panomics) uses virus-derived amphipathic MPG
peptides that surround the siRNA, diffuse through the lipid bilayer membrane, and
release the contents inside the cell. Knockdown of Atp10c mRNA in adipocytes was
investigated using two concentrations and three time points (Figure 21). Transient
transfection with 30 nM of 5′ Atp10c siRNA using DeliverX transfection reagent yielded
88%, 64%, and 65% knockdown of Atp10c mRNA at 24, 48, and 72 h, respectively. At
the protein level, a 38% knockdown of ATP10C was seen at 48 h (Figure 22).
The use of siRNA can sometimes lead to off-target effects, where the siRNA
binds to and decreases expression of a different gene. In order to determine if the 5′
Atp10c siRNA would lead to off-target effects, the expression of additional genes was
analyzed in 3T3-L1 adipocytes following knockdown of Atp10c (Figure 23). Decreased
Atp10c mRNA expression lead to decreased expression in genes involved in adipogenesis
and/or glucose uptake: CCAAT-enhancer-binding protein α (C/EBPα), glucose
transporter 4 (GLUT4), and PPARγ. These results support a role for Atp10c in the
process of adipogenesis and/or glucose uptake.
Atp10c siRNA can be used to transiently knockdown Atp10c/ATP10C expression
in 3T3-L1 preadipocytes or adipocytes as well as to transiently knockdown
Atp10c/ATP10C expression in 3T3-L1 cells throughout adipogenesis (Figure 24).
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Figure 21: Standardization of Atp10c mRNA knockdown in 3T3-L1 adipocytes
using siRNA.
RT-PCR analysis was used to determine Atp10c mRNA expression in 3T3-L1 adipocytes
treated with 15 nM or 30 nM of 5′ Atp10c siRNA for 24, 48, or 72 h. β-actin is used as
an internal control. Expression of Atp10c mRNA is denoted as arbitrary units (A.U.) and
represented as the fold change normalized to β-actin.
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Figure 22: ATP10C protein is knocked down in 3T3-L1 adipocytes using siRNA.
Western blotting was used to determine ATP10C protein expression in 3T3-L1
adipocytes treated with 30 nM of 5′ ATP10C siRNA for 24, 48, or 72 h; β-TUBULIN is
used as an internal control. Expression of ATP10C is denoted as arbitrary units (A.U.)
and represented as the fold change normalized to β-TUBULIN. *P<0.05, **P<0.01.
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Figure 23: Expression of additional genes in 3T3-L1 adipocytes following Atp10c
mRNA knockdown using siRNA.
RT-PCR analysis was used to determine mRNA expression of ap2, PPARγ, GLUT4, and
C/EBPα in 3T3-L1 adipocytes treated with 30 nM of 5′ Atp10c siRNA for 24 h. β-actin
is used as an internal control. Expression of each gene is denoted as arbitrary units
(A.U.) and represented as the fold change normalized to β-actin. *P<0.01, ***P<0.001.
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Figure 24: Atp10c mRNA expression is knocked down throughout differentiation
using siRNA.
RT-PCR analysis was used to determine Atp10c mRNA expression in 3T3-L1 cells
collected at days 0, 3, 4, and 7 post-induction treated with 5′ Atp10c siRNA, which was
added every time the media was changed. β-actin is used as an internal control.
Expression of Atp10c is denoted as arbitrary units (A.U.) and represented as the fold
change normalized to β-actin. ***P<0.001.
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Atp10c siRNA can be used to knockdown gene expression in primary cultures
After confirming that siRNA could be used to transiently knockdown Atp10c in
3T3-L1 cells, the effect of siRNA in primary preadipocytes differentiated in culture was
monitored (Figure 25). In primary preadipocytes, 200 nM of 5′ Atp10c siRNA showed a
94% and 91% knockdown after 24 and 48 h, respectively. In primary adipocytes, 30 nM
of 5′ Atp10c siRNA showed a 51% knockdown after 24 h.
Glucose uptake is increased following knockdown of Atp10c/ATP10C with siRNA
The last part of the insulin signaling pathway after insulin binds to the insulin
receptor is the uptake of glucose into the cell mediated by GLUT4. In order to study the
effect of decreased Atp10c/ATP10C on glucose uptake in 3T3-L1 cells, the process was
first standardized (Figure 26). Treatment of cells with 100 nM insulin for 30 min showed
a 3-fold increase in glucose uptake compared to untreated cells. Glucose uptake was next
measured in 3T3-L1 adipocytes following knockdown of Atp10c/ATP10C with siRNA.
There was a 4-fold or 10-fold increase in glucose uptake of transfected adipocytes
compared to control adipocytes after 24 or 48 h, respectively (Figure 27).
Subcellular fractionation of 3T3-L1 cells can be used to localize ATP10C protein
Following treatment with insulin, the movement of ATP10C between cellular
fractions can be investigated to elucidate a potential role of ATP10C in the insulin
signaling pathway. Subcellular fractionation of 3T3-L1 preadipocytes and adipocytes
was performed (Figure 28). Following standardization of the fractionation procedure,
cells were treated with or without insulin to localize the ATP10C protein (Figures 29,
30). The concentration of Na+K+-ATPase, which remains the same in the plasma
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Figure 25: Primary cultures treated with Atp10c siRNA show a knockdown in
mRNA levels.
RT-PCR analysis was used to determine Atp10c mRNA expression in primary
preadipocytes (A) and adipocytes (B) collected from mouse tissue, plated, and
differentiated in culture. Cells were treated with 5′ Atp10c siRNA for 24 h. β-actin is
used as an internal control. Expression of Atp10c is denoted as arbitrary units (A.U.) and
represented as the fold change normalized to β-actin. *P<0.01, **P<0.05.
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Figure 26: Standardization of glucose uptake in 3T3-L1 adipocytes.
Glucose uptake was used to determine the amount of 2-deoxyglucose incorporated into
3T3-L1 adipocytes. Standardization of concentration and time for insulin stimulation
was performed. Glucose uptake is denoted as the fold change of glucose uptake with
insulin stimulation normalized to basal glucose uptake (without the addition of insulin).
*P<0.01, **P<0.05, ***P<0.001.
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Figure 27: Treatment of 3T3-L1 adipocytes with Atp10c siRNA increases glucose
uptake.
3T3-L1 adipocytes were treated with 30 nM of 5′ Atp10c siRNA for 24 h or 48 h; glucose
uptake was used to determine the amount of 2-deoxyglucose incorporated into the
adipocytes. Glucose uptake in transfected cells is denoted as the fold change of glucose
uptake normalized to glucose uptake in control cells. ***P<0.001.
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Figure 28: Subcellular fractionation of 3T3-L1 preadipocytes and adipocytes.
Western blotting was used to determine ATP10C and GLUT1 protein expression in 3T3L1 preadipocytes (A) and adipocytes (B) fractionated into whole cell lysate (WCL), high
density microsomal (HDM), low density microsomal (LDM), mitochondrial nuclear
(MN), and plasma membrane (PM) fractions.
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Figure 29: Subcellular fractionation of 3T3-L1 adipocytes treated with insulin.
Western blotting was used to determine ATP10C, Na+K+-ATPase, and GLUT4 protein
expression in 3T3-L1 adipocytes treated without (A) or with (B) 1 µM insulin for 30 min.
Proteins were fractioned into whole cell lysate (WCL), high density microsomal (HDM),
low density microsomal (LDM), mitochondrial nuclear (MN), and plasma membrane
(PM) fractions.
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Figure 30: A second subcellular fractionation of 3T3-L1 adipocytes treated with
insulin.
Western blotting was used to determine ATP10C and GLUT4 protein expression in 3T3L1 adipocytes treated without (A) or with (B) 1 µM insulin for 30 min. Proteins were
fractioned into whole cell lysate (WCL), high density microsomal (HDM), low density
microsomal (LDM), and plasma membrane (PM) fractions.
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membrane, and GLUT4, which increases in the plasma membrane, both serve as internal
controls.

Discussion
Atp10c is a type IV P-type ATPase located on mouse chromosome 7.
Heterozygous mice inheriting a maternal deletion of the Atp10c gene become obese and
exhibit hyperinsulinemia, hyperlipidemia, and hyperglycemia traditionally associated
with T2DM [8, 66, 141]. In the study of metabolic diseases, the ability to distinguish
between primary and secondary effects is a major problem. Given that Atp10c
heterozygotes are obese and exhibit these metabolic abnormalities, it becomes difficult to
understand if changes in glucose and lipid metabolism directly arise from alterations in
ATP10C activity or if they are due to secondary complications. Therefore, the present
study was initiated to define the functional importance of Atp10c in a cell. A cell system
expressing Atp10c must first be established in order to use this system to identify factors
modulating Atp10c expression and elucidate a biological role for Atp10c/ATP10C in the
process of adipogenesis and the insulin signaling pathway.
The commercially available Swiss murine 3T3-L1 cell line [10] was used as an in
vitro model while primary preadipocytes isolated from mouse adipose tissue and
differentiated in culture were used as an ex vivo model. In order to use these systems in
this project, the presence of Atp10c needed to first be demonstrated. The expression of
Atp10c mRNA was shown in both the undifferentiated and differentiated adipocytes in
vitro (Figure 8) and ex vivo (Figure 9). Quantitative analysis showed that Atp10c mRNA
is 2-fold down-regulated in 3T3-L1 adipocytes during differentiation (Figure 8). This
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decrease in expression was also seen in primary preadipocytes and adipocytes isolated
from mouse adipose tissue (Figure 9A). However, Atp10c expression was slightly upregulated in primary adipocytes differentiated in culture (Figure 9B). The addition of 100
nM insulin to primary adipocytes also slightly increased Atp10c expression (Figure 18).
Thus, the up-regulation in primary adipocytes differentiated in culture is most likely due
to the higher concentration of insulin present in the differentiation media that is only used
for primary cultures. It has been previously shown that insulin is may increase or
decrease expression of a number of mRNAs coding for obesity and diabetes genes [157,
158]. In this study, it may stimulate up-regulation of Atp10c in primary adipocytes by
increasing the turnover rate or the stability of Atp10c mRNA.
The down-regulation of Atp10c is opposite to that observed for resistin and
PPARγ (Figures 8, 14), which are key molecules involved in the regulation of
adipogenesis. This decrease during differentiation is also seen with preadipocyte factor1, or pref-1, a member of the epidermal growth factor (EGF)-like family of proteins
[159]. Similar to Atp10c, Pref-1 is highly expressed in undifferentiated cells and downregulated during differentiation, serving as an excellent marker for preadipocytes. The
DNA sequence element involved in this differentiation-dependent down-regulation has
already been identified and the protein binding characterized [160]. Due to the fact that
Atp10c shows a differentiation-dependent expression pattern similar to pref-1, further
research on Atp10c may elucidate a complementary role as a negative regulator of
adipogenesis.
Upon confirmation of the decrease in Atp10c mRNA expression during
differentiation in these cell systems, the next step was to characterize the protein
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expression of ATP10C. Based on the molecular weight, a protein band at 169 kDa was
expected in Western blotting; a band at this size was faint or unseen with the first sample
loading buffer used. After testing multiple sample loading buffers with or without a
reducing agent (Figure 10), protein bands in the high molecular weight range of 140 kDa
and the low molecular weight range of 70 kDa were apparent with certain sample loading
buffers. Due to the fact that neither of these bands was the expected molecular weight of
ATP10C, a peptide neutralization experiment was performed (Figure 11). This
demonstrated that the actual band for ATP10C using the antibody generated against the
15 amino acid peptide located between transmembrane helices four and five on the
cytoplasmic loop is 70 kDa.
Although Atp10c mRNA decreased during differentiation, ATP10C protein was
shown to increase (Figure 12). This was an unexpected result because traditionally the
transcribed mRNA is translated into an amino acid polypeptide chain that codes for a
protein; as mRNA levels increase, protein levels would also be expected to increase.
There are multiple potential correlations between the molecular weight discrepancy and
the opposite pattern of Atp10c mRNA and ATP10C protein expression.
DNA contains genes that code for a unique protein. Protein synthesis begins
when the sequence of DNA is transcribed into mRNA in the nucleus of a cell. The
mRNA is processed and then moves out into the cytoplasm, where it is translated into a
polypeptide chain that codes for a specific protein with the use of ribosomes located on
the endoplasmic reticulum (ER).
Since ATP10C is located in the ER once it is synthesized before transportation to
another part of the cell, one reason for a lower molecular weight band may be due to
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endoplasmic reticulum-associated protein degradation (ERAD). Conditions that interfere
with the normal functioning of the ER are collectively known as ER stress [161]. One
response to ER stress is the degradation of misfolded or unassembled proteins by ERAD
[162]. This degradation may result in the production of a smaller protein, potentially
explaining the 70 kDa ATP10C band when it was expected to be 169 kDa. ER stress has
been shown to not only be related to numerous monogenic diseases [163], but also to the
more complex diseases of obesity [164] and T2DM [161, 165]. Özcan et al and others
have identified ER stress as a molecular link between obesity, decreased action of insulin,
and the development of T2DM [164, 166]. Using cell culture and mouse models, it has
been shown that obesity causes ER stress, which may correlate to the increased
production of the 70 kDa ATP10C protein during differentiation. As the 3T3-L1 cells
become adipogenic, there may be an increase in the degree of ER stress, which leads to
ERAD and an increased production of the 70 kDa degraded ATP10C protein.
If the ATP10C protein is not misfolded or unassembled in the ER to be targeted
for ERAD, a molecular chaperone should transport ATP10C from the ER to the plasma
membrane. However, a defect in the molecular chaperone would keep ATP10C in the
ER, allowing it to be targeted for ERAD as described above. Leptin is a hormone
secreted in adipocytes that has been shown to modulate the secretion of the
proinflammatory cytokine interferon-γ (IFN-γ). Research in the Pacifico laboratory
found that there is an increased production of IFN-γ in obese children [167]. Combining
this discovery with research concluding that IFN-γ induces severe ER stress through the
inhibition of molecular chaperones [165], ATP10C may still remain in the ER after
protein folding due to a defect in the molecular chaperone. The increased ER stress
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caused by adipogenesis would again degrade the ATP10C protein remaining in the ER,
producing the smaller 70 kDa form.
Lastly, a post-translational modification of ATP10C may cleave the protein,
resulting in multiple fragments. The antibody used in these experiments may only be
recognizing the N terminal portion of the cleaved protein. The difference in the expected
versus resulting protein size may be related to the antibody, which was generated against
a small region of the peptide. In order to prove or disprove that the protein is actually 70
kDa, it will be necessary to generate a new ATP10C antibody against a different region
of the peptide.
The process of adipocyte differentiation is associated with a large number of cisand trans-acting factors [106, 168, 169]. The regulation of different genes at distinct
times after the exposure of cells to differentiation conditions suggests the existence of a
regulatory hierarchy or cascade of events [110, 170]. PPARγ is considered to be the
master regulator of adipogenesis [110] and controls the expression of adipocyte genes.
After investigating the effect of the anti-diabetic drugs MCC555 and TGZ [109, 130] on
Atp10c expression, it was shown that these PPARγ agonists promoted adipogenesis and
further decreased Atp10c expression (Figure 13). Adipocytes treated with the PPARγ
antagonist GW9662 [156] alone showed Atp10c expression similar to that in control cells
treated with the vehicle DMSO. However, the combination of the PPARγ agonist and
antagonist demonstrated that GW9662 was capable of rescuing some of the decrease in
Atp10c expression due to MCC555 or TGZ alone.
Because both MCC555 and TGZ are anti-diabetic drugs and PPARγ agonists that
decreased Atp10c expression, the next experiment to gain further insight into the
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transcriptional control of Atp10c during adipogenesis used only MCC555 (Figure 14).
Confirming that Atp10c is down-regulated in adipogenesis, high levels of Atp10c were
expressed at day 3 that gradually decreased throughout differentiation as opposed to the
low levels of PPARγ expression that gradually increased throughout differentiation.
Cells treated with MCC555 and/or GW9662 showed a similar pattern of decreased
Atp10c expression and increased PPARγ expression. This opposite regulation of Atp10c
and PPARγ suggests a potential role for Atp10c as a PPARγ modulator.
MCC555 and TGZ are members of the thiazolidinedione (TZD) class of drugs
used to treat and manage T2DM through the improvement of insulin sensitivity [115].
These PPARγ agonists act to increase transcription of PPARγ, which then binds to a
peroxisome proliferator hormone responsive element (PPRE) usually located in the
promoter region in order to increase or decrease gene expression. MCC555 and TGZ
both decreased Atp10c gene expression while increasing adipocyte differentiation, similar
to the inhibition of leptin gene expression in 3T3-L1 adipocytes following treatment with
TZDs [117]. This is interesting because TZDs are known to increase adipogenesis and
leptin is predominantly expressed in fat cells. These results suggest that the negative
regulation of leptin by TZDs may indicate that these compounds induce a state of
adipocyte differentiation that is subtly different from that induced by the differentiation
cocktail.
Due to the fact that Atp10c was expressed and levels were modulated during the
differentiation of 3T3-L1 preadipocytes to adipocytes, the regulation of Atp10c mRNA
expression by effector molecules of glucose and fat metabolism in undifferentiated and
differentiated cells was next investigated using the hormonal factors insulin,
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dexamethasone, and isoproterenol. Although there was no significant change in Atp10c
expression in 3T3-L1 or primary preadipocytes, Atp10c mRNA increased in 3T3-L1
(Figure 17) or primary (Figure 18) adipocytes when treated with insulin or the
glucocorticoid dexamethasone. There was a slight decrease in expression following
treatment with the β-adrenergic receptor isoproterenol, although this was not statistically
significant. These results suggest transcriptional control of Atp10c expression by
hormonal factors during differentiation. Insulin is already known to positively or
negatively regulate a number of mRNAs coding for obesity and diabetes genes [157,
158]. In this study, it may stimulate Atp10c production in 3T3-L1 adipocytes by
increasing the turnover rate or the stability of Atp10c mRNA. Dexamethasone induces
insulin resistance and stimulates Atp10c production, which is similar to its effect on
resistin and ob gene expression and leptin production [171]. In contrast, the lack of a
significant effect by isoproterenol suggests that Atp10c expression is not controlled by
adrenoreceptors (β-adrenergic factors) in 3T3-L1 adipocytes [172].
Signaling through the insulin pathway is critical for the regulation of intracellular
and blood glucose levels and the avoidance of diabetes. Insulin binds to its receptor
leading to the autophosphorylation of the β-subunits and the tyrosine phosphorylation of
insulin receptor substrates (IRS-1, 2, 3). IRS phosphorylates the SH2 domain of the
tyrosine phosphatase Shp2 and the SH3 domain of the adaptor molecule Grb2. Activated
Grb2 recruits Sos1 that, in turn, activates the Ras signaling pathway and gene
transcription. IRS also activates phosphoinositide 3-kinase (PI3K) through its SH2
domain, thus increasing the intracellular concentration of PIP2 and PIP. This, in turn,
activates phosphatidylinositol phosphate-dependent kinase-1 (PDK-1), that subsequently
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activates a serine-threonine protein kinase Akt/PKB resulting in the translocation of the
glucose transporter (GLUT4) from cytoplasmic vesicles to the cell membrane. In all
types of obesity and diabetes, the major abnormality lies in the glucose uptake system
[93, 96, 97, 173].
With the recent advent of siRNA technology, RNAi-based gene silencing in
cultured 3T3-L1 adipocytes has proven to be valuable in examining elements crucial for
the insulin signaling pathway leading to translocation of glucose transporter 4 (GLUT4)
to the plasma membrane and for adipocyte differentiation [135-137]. Gene silencing in
cultured mammalian cells is being used as an effective way to quickly screen the
requirement of a specific gene for a biological function. In order to investigate the
biological role of Atp10c/ATP10C in the insulin signaling pathway, gene and protein
levels were silenced using siRNA technology. Knockdown of Atp10c/ATP10C was first
standardized in both 3T3-L1 preadipocytes (Figures 19, 20) and adipocytes (Figures 21,
22) and shown to be knocked down throughout differentiation (Figure 24) that also
affected several key factors of adipogenesis (Figure 23). Then, glucose uptake was used
to investigate a biological role for ATP10C in the insulin signaling pathway. When
ATP10C was silenced, glucose uptake increased (Figure 27). This also supports the
MCC555 and TGZ data because TZDs are anti-diabetic drugs that improve insulin
sensitivity by increasing the uptake of glucose, and they also decreased the expression of
Atp10c. Similarly, when Atp10c/ATP10C was decreased with siRNA, glucose uptake
was significantly increased. Knockdown of PPARγ has been shown to attenuate glucose
uptake in 3T3-L1 adipocytes [113], again corroborating the opposing regulation of
Atp10c and PPARγ. Park et al [174] demonstrated analogous findings to the Atp10c data
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using cilostazol, which stimulated transcriptional activity of PPARγ in human umbilical
vein endothelial cells and increased glucose uptake.
The in vitro glucose uptake results using 3T3-L1 adipocytes are opposite of those
in the whole animal model [141], where knockdown of ATP10C in the heterozygous
mutant mice led to decreased glucose uptake. This demonstrates the difficulty in
understanding if changes in glucose and lipid metabolism in a whole animal model
directly arise from alterations in ATP10C activity or if they are due to secondary
complications.
To further investigate the cellular localization of ATP10C with and without
insulin stimulation, subcellular fractionation of 3T3-L1 preadipocytes and adipocytes was
performed (Figure 28). Following stimulation with insulin, it appeared that ATP10C
expression increased in the plasma membrane (Figures 29, 30). However, it becomes
difficult to interpret these results due to cross-contamination between fractions.
Based on these results and the current literature, Atp10c/ATP10C does have a role
in the insulin signaling pathway and may have a potential role in adipogenesis.
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CHAPTER 4. CONCLUSIONS AND FUTURE DIRECTIONS
The aim of this study was to investigate the biological role of Atp10c/ATP10C, a
type IV P-type ATPase located on mouse chromosome 7, in the process of adipogenesis
and the insulin signaling pathway. Heterozygous mice inheriting a maternal deletion of
the Atp10c gene become obese and exhibit metabolic abnormalities (hyperinsulinemia,
hyperlipidemia, and hyperglycemia) traditionally associated with T2DM [8, 66, 141].
The ability to distinguish between primary and secondary effects is a major problem with
the use of a whole animal model, making it hard to understand if changes in glucose and
lipid metabolism directly arise from alterations in ATP10C activity or if they are due to
secondary complications. Therefore, the commercially available Swiss murine 3T3-L1
cell line was used as an in vitro model to study changes in Atp10c/ATP10C expression
and primary preadipocytes isolated from mouse adipose tissue and differentiated in
culture were used as an ex vivo model.
Atp10c mRNA was 2-fold down-regulated during adipogenesis, similar to the
known inhibitor of adipocyte differentiation, pref-1 [159, 160, 175-180]. This is
interesting because most of the genes related to obesity are up-regulated during
adipogenesis [105, 181-183]. Previous research has shown that constitutive expression of
pref-1 inhibits the process of adipogenesis, suggesting that pref-1 functions as a negative
regulator of the differentiation process [159]. Due to the fact that Atp10c shows a similar
differentiation-dependent down-regulation to pref-1, a future experiment with the
constitutive expression of Atp10c would elucidate its effect on adipogenesis and its role
in regulating the process of differentiation.
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Interestingly, ATP10C protein was up-regulated throughout differentiation and
showed an unexpected protein band at a lower molecular weight of 70 kDa. This
discrepancy may be due to endoplasmic reticulum-associated protein degradation
(ERAD) if the protein is misfolded or unassembled in the ER or if there is a defect in the
molecular chaperone that would cause ATP10C to remain in the ER and be degraded. It
may also be due to a post-translational modification that cleaves the protein so that the
antibody that was generated against a 15 amino acid peptide sequence between
transmembrane loops four and five on the N terminus is only recognizing one part of the
cleaved protein. To resolve these data, generation of a second antibody against a peptide
sequence located in a different region on the C terminal end may show the same band at
70 kDa, supporting ERAD of ATP10. However, a protein band at a different molecular
weight would support post-translational protein cleavage.
PPARγ is considered to be the master regulator of adipogenesis [110], controlling
the expression of adipocyte genes. Throughout differentiation, Atp10c and PPARγ
mRNAs were oppositely regulated, suggesting a potential role for Atp10c as a PPARγ
modulator. Treatment of 3T3-L1 cells with the PPARγ agonists MCC555 and TGZ
demonstrated increased adipogenesis and decreased expression of Atp10c. These PPARγ
agonists are also anti-diabetic drugs that act to improve insulin sensitivity in diabetic
patients by increasing glucose uptake. Silencing Atp10c/ATP10C with siRNA, similar to
the decreased expression seen following treatment with the PPARγ agonists, led to
increased glucose uptake, again supporting the role of Atp10c as a PPARγ modulator. To
further investigate this potential function, the silencing of PPARγ in 3T3-L1 cells before,
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during, and after differentiation followed by the subsequent analysis of its affect on
Atp10c expression would be beneficial.
Due to the fact that PPARs bind to PPREs in order to activate or suppress gene
expression, analysis of the Atp10c gene sequence may also provide valuable evidence of
the presence a PPRE. If a PPRE is present, experiments should also be undertaken to
confirm if the site is functional, similar to the experiments Frohnert et al performed to
determine the functionality of the murine fatty acid transport protein (FATP) gene PPRE
[184].
The knockdown of ATP10C in 3T3-L1 adipocytes led to increased glucose
uptake, but another experiment to examine its role in glucose uptake would be to silence
ATP10C expression throughout differentiation to see what would happen if ATP10C was
completely ablated in preadipocytes. Glucose uptake involves the translocation of
GLUT4 from the inner membrane to the outer membrane of a cell in order to take up the
glucose from the cytosol. Because ATP10C may have a potential role in this process,
future work could be to localize the protein in 3T3-L1 cells. The subcellular
fractionation experiments showed that ATP10C could be localized and the effect of
insulin stimulation monitored; however, there was a question of cross-contamination
between fractions, making it difficult to interpret the results. Additionally, a tremendous
number of cells are needed for subcellular fractionation that would render this experiment
expensive and unfeasible to look at the effect of transient Atp10c knockdown with
siRNA. Immunofluorescence microscopy is a technique currently used in research [125,
185] that represents as a more money-conscious and effective way to localize proteins in
a cell.
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Since Atp10c has been successfully knocked down using transient siRNA
transfection, which did show an effect on the insulin signaling pathway, experiments can
be undertaken to knockdown Atp10c in the generation of a stable cell line. This cell line
could also be used for subcellular fractionation experiments because there is no longer a
need for the expensive siRNA used in transient transfections.
All of the work for this project was performed using the mouse embryonic
fibroblast-adipose like 3T3-L1 cell line or primary preadipocytes isolated from mouse
adipose tissue and differentiated in culture. However, insulin resistance is due to a defect
in both adipose tissue, accounting for 5-10% of the glucose uptake, and skeletal muscle,
which disposes of the majority of glucose [92, 94, 96, 97, 186, 187]. Dhar et al showed
that Atp10c expression was significantly down-regulated in Atp10c heterozygous mice
fed a high-fat diet for 4 and 12 weeks; this decrease was seen only in the soleus muscle
and not the adipose tissue at the earlier timepoint [141]. Thus, a future direction for this
project would be to examine changes in Atp10c/ATP10C expression using the mouse
muscle cell line C2C12 [188, 189]. A second benefit to looking at this cell line is that
obesity does not cause ER stress in the muscle tissue [164], so this may help support or
refute ERAD of ATP10C protein due to ER stress caused by increased adiposity.
In summary, Atp10c and the master regulator of adipogenesis PPARγ are
oppositely regulated and knockdown of Atp10c/ATP10C increases glucose uptake in
3T3-L1 adipocytes. This supports a biological role for Atp10c/ATP10C the insulin
signaling pathway and a potential role in adipogenesis, although further experimentation
is necessary to elucidate the exact function.
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APPENDIX
RNA extraction and purification of primary preadipocytes and adipocytes from
mouse tissue
1. Clean homogenizer.
a. Rinse with clean deionized water, holding beaker underneath to catch drips.
b. Spray with 70% EtOH, and wipe with KimWipe.
c. Rinse with DEPC water, holding beaker underneath to catch drips.
d. Run homogenizer in DEPC water in clean beaker.
e. Squirt RNase AWAY on KimWipe, and wipe homogenizer.
2. Weigh tissue into 50 ml tube and add 10 ml of trizol per 1 g of tissue.
3. Homogenize trizol/tissue mix until there are no remaining clumps, approximately 10
seconds and immediately place sample in ice.
4. Repeat steps #1-3 for all samples.
5. Place samples under hood and leave at room temperature for 10 minutes.
6. Under hood, add 5 ml of chloroform per 1 g of tissue to each sample.
7. Vortex samples, place under hood, and leave at room temperature for 5 minutes.
8. Centrifuge at 3K, 4-10°C, 20 minutes.
9. Transfer top layer with pipette to 10 ml tube. If the top layer is “dirty” (contaminated
by bottom layer), centrifuge again, and repeat step #8.
10. Under hood, add 5 ml of isopropyl alcohol per 1 g of tissue to each sample.
11. Vortex, place under hood, and leave at room temperature for 20 minutes.
12. Centrifuge at 3K, 4-10°C, 20 minutes.
13. Collect the pellet by dumping the liquid into a separate container without disturbing
the pellet.
14. Add 10 ml of 70-75% ethanol alcohol per 1 g of tissue to each sample.
15. Vortex to disperse the pellet.
16. Centrifuge at 3K, 4-10°C, 20-60 minutes.
17. Collect the pellet by dumping the liquid into a separate container without disturbing
the pellet.
18. Tilt the tubes until they are approximately upside down, and let the tubes sit under the
hood for 10 minutes to dry the pellet.
19. Resuspend pellet in 100 µl of sterile water and transfer to 1.5 ml tube.
20. Make first mix by combining RLT buffer and 2-mercaptoethanol (3 ml of RLT + 30
µl of 2-mercaptoethanol is enough for 6 samples). Vortex mix.
21. Add 350 µl of first mix to each sample. Vortex and centrifuge samples.
22. Add 250 µl of ethanol to each sample. Vortex and centrifuge samples.
23. Transfer sample mix into the pink column.
24. Make sure centrifuge lid is in place, and then centrifuge samples for 15 seconds.
25. Pull column out. Dump liquid out of 1.5 ml tube. Replace column in top of 1.5 ml
tube.
26. Add 500 µl of RPE buffer to pink column.
27. Make sure centrifuge lid is in place, and then centrifuge samples for 15 seconds.
28. Repeat steps #25-27.
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29. Pull column out. Dump liquid out of 1.5 ml tube. Replace column in top of 1.5 ml
tube.
30. Make sure centrifuge lid is in place, and then centrifuge samples for 1 minute.
31. Move pink column to 1.5 ml tube with ridged edges (pre-labeled).
32. Add 50 µl of DEPC to center of white material without touching white material.
33. Make sure centrifuge lid is in place, and then centrifuge samples for 1 minute.
34. Centrifuge again if significantly less than 50 µl of water is present at bottom of tube.
35. Toss pink column and keep 1.5 ml tube with elutant.
36. Quantitate RNA using Biophotometer.
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RNA extraction and purification of 3T3-L1 cells and primary preadipocytes and
adipocytes plated and differentiated in culture
1. Add 400 µl RLT buffer from Qiagen kit for a 60 mm dish (600 µl for a 100 mm dish).
If making RNA immediately, add β-mercaptoethanol to RLT buffer (1 µl βmercaptoethanol per 100 µl RLT buffer). If collecting RNA samples and storing at 80°C, do not add β-mercaptoethanol until you are ready to make the RNA.
2. Scrape cells and transfer to a round bottom tube from Qiagen kit if making RNA
immediately or transfer to a small Eppendorf tube if storing at -80°C.
3. Syringe each sample up and down five times using a 20-guage needle.
4. Add an equal amount of 70% ethanol (400 µl or 600 µl).
5. Transfer solution to pink column (700 µl at a time) and centrifuge for 20 seconds at
13K.
6. Dump liquid out of the bottom tube and add 700 µl RW1 buffer from Qiagen kit to
the pink column; centrifuge for 20 seconds at 13K.
7. Dump liquid out of the bottom tube and add 500 µl RPE buffer from Qiagen kit to the
pink column; centrifuge for 20 seconds at 13K. Repeat this step again.
8. Dump liquid out of the bottom tube and centrifuge for 1 minute at 13K.
9. Move pink column to 1.5 ml tube (pre-labeled) from Qiagen kit. Add 50 µl RNasefree water from Qiagen kit to center of white material in column.
10. Centrifuge samples for 1 minute.
11. Toss pink column and keep 1.5 ml tube with elutant.
12. Quantitate RNA using Biophotometer.
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Isolation and differentiation of primary preadipocytes (PA) and adipocytes (Ad)
1. Sacrifice mice by CO2 asphyxiation.
2. Collect adipose tissue from mice.
3. Mince tissue into small pieces and weigh. Add approximately 2 g tissue to each 50
ml Falcon tube.
4. Add 10ml KRB buffer + 20mg of collagenase (2 mg/ml) to each 2 g of tissue.
5. Shake at 37ºC, 25′. If there is still a large amount of floating pieces, continue to
shake until there are very few pieces.
6. Filter through 100 µM mesh and rinse with 5ml KRB + collagenase.
7. Centrifuge at 800rpm (low speed), 10′.
8. Collect floating Ad using coated pipets, add equal volume HBSS, store on ice
temporarily.
9. Add 5 ml FACS buffer to PA/KRB + collagenase tube; centrifuge at 1500rpm, 10′.
10. Loosen PA pellet by gently flicking the tube, rinse with ~0.5ml HBSS to disperse
clumps, and treat with 5 ml 1X RBC (red blood cell) lysis buffer (eBioScience).
11. Leave RBC treated PA at RT, 4′.
12. Add 5 ml FACS buffer to PA/lysis buffer tube.
13. Centrifuge PA and Ad at 800rpm (low speed), 10′.
14. Remove HBSS from the bottom of Ad using coated pipets.
15. Store Ad at -80ºC for later use.
16. Remove FACS buffer from PA pellet and wash 1X with new FACS buffer.
17. Centrifuge PA at 800rpm (low speed), 10′.
18. Remove FACS buffer from PA pellet.
19. Count and plate primary preadipocytes (at a density of ~7.5 x 105 cells/well) if using
in culture or store at -80ºC for later use.
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Cell Work Medias
Growth Media (GM)
 1 L DMEM
 100 ml 10% FBS
 10 ml 1% P/S
Differentiation Media (DM)
 10 ml GM
 110 µl of 0.5 mM isobutyl-methyl-xanthine (MIX)
(Sigma I-5879, dissolve 250 mg in 25 ml of 95% ethanol)
 10 µl of 1µM dexamethasone
(Sigma D-4902, dissolve 100 mg in 100 ml of 95% ethanol)
 1 µl of 1 µg/ml insulin
(Sigma I-9278, 1.7 mM ready to use)
 10 µl of 10 mM troglitazone (TGZ)
(Cayman Chemical 71750, dissolve 10 mg in 2.26 ml DMSO)
Maintenance Media (MM)
 10 ml GM
 1 µl of 1 µg/ml insulin
 10 µl of troglitazone (TGZ)
High Insulin Media (HI)
 10 ml GM
 10 µl of 1 µg/ml insulin
Thiazolidinediones (TZDs)
 1 µl of 10 mM MCC555 per 1 ml media
 1 µl of 10 mM TGZ per 1 ml media
 1 µl of 10 mM GW9662 per 1 ml media

105

Oil Red O staining
For all additions and washes, use a volume equal to the volume of media used for
the dish. For example, use 2 ml volume for all 60 mm dishes.
1. Prepare ORO solution by dissolving 0.039 g ORO powder in 5.6 ml of 85%
propylene glycol. Warm ORO in water bath (60°C) before use.
2. Rinse dish twice with HBSS.
3. Add 1% formalin to well, leave at RT 5′.
4. Remove formalin (DO NOT discard waste in sink).
5. Add 85% propylene glycol, leave at RT 5′ two times.
6. Add ORO, agitate slightly using Belly Dancer on low setting (3-4) at RT, 20′.
7. Add 85% propylene glycol, leave at RT 3′.
8. Rinse dish with tap water until there is no more residual ORO rinsed off (2-5 times).
9. Add hematoxycin counterstain, leave at RT 30 sec.
10. Rinse dish with tap water until there is no more/minimal hematoxycin counterstain
rinsed off (2-5 times).
11. Photograph dish.
Oil Red O staining for Quantification
Reagents
ORO stock
 0.7 g ORO
200 ml Isopropanol
 Stir overnight, then filter with 0.2 µm and store at 4°C
ORO Working Solution
 6 parts ORO stock
4 parts dH2O
 Mix and let sit at RT, 20′, then filter with 0.2 µm
1.
2.
3.
4.
5.
6.
7.

Remove most of the medium and wash once with 1X PBS.
Add 10% formalin and incubate at RT, 5′.
Discard formalin and add the same volume of fresh formalin.
Incubate 1 h or longer at RT.
Wash wells with 60% isopropanol.
Let the wells dry completely for 5′.
Add ORO working solution for 20′ (do not touch walls of the wells) (on the belly
dancer).
8. Remove all ORO and IMMEDIATELY add dH2O; wash with H2O four times.
9. Photograph dish if desired.
10. Remove all water and let dry at 37° for 10′.
11. Elute ORO by adding 100% isopropanol; incubate about 15′ (can be longer).
12. Pipet the isopropanol with ORO up and down several times to be sure that all
ORO is in the solution.
13. Measure OD at 540 nm. Read 200 µl in a 96 well plate.
14. Use 100% isopropanol as a blank and isopropanol from an empty well stained as
previously described as a control.
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siRNA Transfections
Preadipocytes
Cells were transfected with 200 nM of Atp10c siRNA.
1. Combine equal volumes of 20 µM Atp10c siRNA and HiPerfect transfection reagent
(40 µl total volume is required per dish).
2. Flick tube to mix and leave at RT for 10′.
3. Add 40 µl of the transfection complex to the medium of each cell culture dish by
gently pipetting into the medium.
4. Gently swirl dishes to disperse the transfection complex.
5. Incubate under standard cell culture conditions.
6. Transfect cells each time the medium is changed.
Adipocytes
Cells were transfected with 30 nM of Atp10c siRNA.
1. Prepare working siRNA transfection complex as follows [145].
Step
1
2

3

4

5

6

Scale-Up Volumes and
Sonication Times
1X
2X
3X

Action
Prepare 5 µM siRNA working stocks using TE buffer.
Dilute 5 µM siRNA working stocks with Buffer-1.
a. Add Buffer-1:
b. SiRNA:
Prepare siRNA Transfection Reagent.
a. Sonicate the siRNA Transfection Reagent:
b. Mix Buffer-2 with:
c. siRNA Transfection Reagent:
d. Vortex and sonicate solution again for:
Form concentrated siRNA transfection complex:
a. Combine appropriate tubes from steps 2 and 3.
b. Briefly vortex and then incubate for 20 min at 37°C.
Prepare complex dilution buffer.
a. Mix Buffer-1 with:
b. Buffer-2:
Prepare working siRNA transfection complex:
a. Add complex dilution buffer to prepared concentrated
siRNA transfection complexes:

37 µl
13 µl

74 µl
26 µl

111 µl
39 µl

3-5 min
42 µl
8 µl
3-5 min

3-5 min
84 µl
16 µl
3-5 min

3-5 min
126 µl
24 µl
3-5 min

200 µl
200 µl

400 µl
400 µl

500 µl
500 µl

300 µl

600 µl

900 µl

2. Wash cells with 1X PBS (1500 µl/well).
3. Add working transfection complex (300 µl/well) and incubate at RT, 3-5′.
4. Add serum-free media (300 µl/well) and incubate under normal cell culture
conditions for 2-4 h.
5. Add complete growth medium (1000 µl/well) and incubate under normal cell culture
conditions for 24-72 h.
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Semi-quantitative RT-PCR and agarose gel
Recipes
50X TAE buffer
 242 g tris-BASE
57.1 ml glacial acetic acid
100 ml 0.5 M EDTA, pH 8.0
 fill to 1 L with nanopure water
 filter solution
1X TAE buffer
 20 ml 50X TAE
 fill to 1 L with nanopure water
1. Prepare 1X cDNA samples using RNA samples and BioRad cDNA kit.
- RNA (1 µg)
sterile H2O (10 µl – volume of RNA used)
5X buffer (2 µl)
enzyme (0.5 µl)
- run cDNA samples in PCR machine using Biorad RT program
2. Prepare RT-PCR primers (P1 + P2).
- 10 µl forward primer (P1)
10 µl reverse primer (P2)
80 µl sterile H2O
3. Prepare RT-PCR samples using cDNA samples.
- 1 µl cDNA
2.5 µl P1 + P2
9 µl H2O
12.5 µl GoGreen Taq Master Mix
4. Run in PCR machine at 54°C annealing, 30 cycles.
5. Prepare 1% agarose gel.
- For a small gel, dissolve 1.25 g agarose in 125 ml fresh 1X TAE buffer.
- For a large gel, dissolve 3.5 g agarose in 350 ml fresh 1X TAE buffer.
- Microwave 1-2 min until all of the agarose dissolves.
- Allow to cool at RT, but do not allow to solidify.
- Add 2 µl ethidium bromide per 1 g agarose.
- Pour into taped gel holder and add well combs.
6. Load RT-PCR samples in 1% agarose gel and run at 75 V for 1 h 15 min for small
gels or 1 h 45 min for large gels.
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RT-PCR primer list

β-actin

ORN 559 (F): 5′−ATGGGTCAGAAGGACTCCTA−3′

520 bp
ORN 560 (R): 5′−CAACATAGCACAGCTTCTCT−3′

Atp10c

ORN 554 (F): 5′−CCTGTGCTCTTCATTCTGGC−3′

886 bp

ORN 555 (R): 5′−CACTGCAGCTGTGAATCTGT−3′
ap2

ORN 697 (F): 5′−GACCTGGAAACTCGTCTCCA−3′

320 bp

ORN 698 (R): 5′−CATGACACATTCCACCACCA−3′
C/EBPα

LACS 130 (F): 5′−CAGTTTGGCAAGAATCAGAGCA−3′

391 bp

LACS 131 (R): 5′−GGGTGAGTTCATGGAGAATGG−3′
GLUT4

LACS 134 (F): 5′−TGGCCCTAAGTATTCAAGTTCTG−3′

168 bp
LACS 135 (R): 5′−TTCCTTCTATTTGCCGTCCTC−3′

PPARγ

LACS 128 (F): 5′−GGTGAAACTCTGGGAGATTC−3′

268 bp

LACS 129 (R): 5′−CAACCATTGGGTCAGCTCTT−3′
resistin

LACS 3 (F): 5′−ACTGAGTTGTGTCCTGCTAAG−3′
LACS 4 (R): 5′−CCACGCTCACTTCCCCGACATC−3′

109

386 bp

Protein extract preparations: total membrane proteins
Reagents
PARP buffer
 50 mM tris, pH 6.8
8 M urea
2% SDS
PARP buffer + protease inhibitors + DTT
 100 µl PARP buffer
1 µl of 100X pi
1 µl of 100 mM DTT
Homogenization buffer
 2 ml of 1 M HEPES, pH 7.5 (to give 20 mM)
1 ml of 1 M KCl (to give 10 mM)
 dilute to 100 ml with nanopure H2O
1. Prepare samples:
a. For tissues, resuspend 500 mg tissue in 5 ml homogenization buffer plus 50 µl pi
per sample. Homogenize with Polytron for 10 sec and pass through 20-gauge
needle 30X.
b. For cells, resuspend pellet in 2 ml homogenisation buffer plus 20 µl pi per
sample. Homogenize through 20-gauge needle 30X.
2. Centrifuge at 800 rpm for 10′ at 4°C.
3. If supernatant is clear, re-pass through needle and centrifuge at 800 rpm.
4. Transfer supernatant to a new tube and centrifuge at 25000 x g (13000 rpm) for 30′ at
4°C.
5. Remove and save supernatant (cytosolic proteins).
6. Resuspend pellet in 100-300 µl PARP buffer + 1 mM DTT + 1 mM pi.
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Protein extract preparations: whole cell lysates with SDS lysis buffer
Reagents
SDS lysis buffer
 2.5 ml of 1 M HEPES (to give 50 mM)
7.5 ml of 1 M NaCl (to give 150 mM)
20 ml of 10% SDS (to give 4% SDS)
 dilute to 50 ml with nanopure H2O
1.
2.
3.
4.
5.

Wash cells twice with PBS at RT.
Add 1 ml of SDS lysis buffer with DTT (10 mM) and pi (1:1000).
Isolate cells with cell scraper and collect in eppendorf tube.
Heat to 100°C for 5 min.
Store at -80°C.

Protein extract preparations: whole cell lysates with RIPA buffer
Reagents
RIPA buffer + inhibitors
 1 ml RIPA buffer
5 µl of 200X Na3VO4
5 µl of 200X NaF
5 µl of 200X PMSF
1 µl of leupeptin
1 µl of aprotinin
1.
2.
3.
4.

Wash cells twice with PBS on ice.
Add RIPA buffer + inhibitors (100 µl per 60 mm dish).
Isolate cells with cell scraper and collect in eppendorf tube.
Store at -80°C.
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Protein extract preparations: subcellular protein fractionations
Recipes
DMEM/BSA
 add 100 mg BSA to 100 ml DMEM
HES buffer
 250 mM sucrose (42.8 g), 20 mM HEPES (2.38 g), 1 mM EDTA (0.15 g)
 dilute to 100 ml with water
 pH to 7.4 and store at RT
HES/pi buffer
 add 1 µl pi for every 1 ml HES buffer
1.12M Sucrose buffer
 add 29.78 g sucrose to 60 ml HES and stir vigorously
 dilute to 100 ml with HES and store at room temperature overnight
 place on ice prior to use
1. serum starve 3T3-L1 cells O/N at 37°C
- wash cells 1X ⊆ DMEM
- add 10 ml DMEM/BSA (1 mg/ml) to each dish
2. remove cells from incubator and bring to benchtop
3. add DMEM with or without insulin (1 µM = 18 µl insulin in 30 ml DMEM) and
incubate flasks at 37°, 30′
4. wash 1X ⊆ 1 ml HES, RT
5. add 3 ml HES/pi to each T75 flask (3 flasks for each sample)
6. scrape 3T3-L1 cells at RT using soft cell scraper
7. collect cells in 50 ml Falcon tubes
8. homogenize 10sec ⊆ Polytron followed by syringing ↑ and ↓ ⊆ 20-gauge needle 30X
≈≈≈≈≈ALL STEPS ON ICE FROM HERE ON OUT≈≈≈≈≈
9. transfer homogenate to black cap (11ml) centrifuge tubes on ice
10. save 300 µl of each as whole cell lysates (WCL) in a 1 ml Eppy tube
11. centrifuge 12000 rpm, 15′, 4°C in 75Ti rotor
12. carefully remove fat layer and transfer infranatant to black cap (11 ml) centrifuge
tubes for further fractionation (~9 ml) – this is the HLC fraction
13. wipe side walls with Kim wipes to remove excess fat
14. resuspend pellet in 9 ml cold HES
15. homogenize ⊆ 20-gauge needle and syringe 5X
16. centrifuge 12000 rpm, 20′, 4°C in 75Ti rotor
17. remove supernatant and discard
18. resuspend pellet in 5 ml HES
19. homogenize ⊆ 20-gauge needle and syringe 5X
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20. overlay homogenate on 6 ml of a 1.12M sucrose cushion made up in HES; top up
tube ⊆ HES
21. centrifuge 25000 rpm, 60′, 4°C in SW28 swinging rotor
22. collect cloudy, “fluffy” interface between top buffer and sucrose cushion (~1 ml)
23. resuspend this interface in 10ml HES in black cap tubes (11 ml)
24. centrifuge 18000 rpm, 30′, 4°C in 75Ti rotor
25. during centrifugation, remove remaining sucrose in SW28 tube and rinse pellet with
HES
- resuspend this pellet in 2 ml HES/pi, transfer to a 2 ml Eppy tube, and label as
mitochondrial/nuclear fraction (MN)
26. after centrifugation, remove supernatant
- resuspend pellet in 150 µl HES/pi, transfer to a 1 ml Eppy tube, and label as
plasma membrane (PM)
27. centrifuge the HLC fraction from earlier 20000 rpm, 30′, 4°C in 75Ti rotor
- transfer supernatant into another black cap centrifuge tube (11 ml) (for LDM
fractionation)
- resuspend pellet in 300 µl HES/pi (HDM)
28. Centrifuge supernatant at 45000 rpm, 1.5h, 4°C
- discard supernatant (cytosolic fraction)
- resuspend pellet in 200 µl HES/pi (LDM)
29. BCA assay to quantitate proteins
- 9 standards in duplicate, all samples in duplicate
- 200 µl mix per well of 50 parts A : 1 part B (1 ml A + 20 µl B)
- assay: 10 µl standard OR 1 µl sample + 9 µl PBS with 200 µl mix
- 37°C, 30′
- 10 samples + 9 standards = 19 in duplicate = 38 total x 200 µl = 7600 µ,
8 ml A + 160 µl B
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WCL fraction
12000rpm, 15′, 4°C

infranatant

pellet

HLC fraction

resuspend in 9ml HES
homogenize 5X
12000rpm, 20′, 4°C

20000rpm, 30′, 4°C

supernatant

pellet
resuspend in
300µl HES/pI

discard
supernatant

HDM fraction

pellet
resuspend in 5ml HES
homogenize 5X
overlay sucrose cushion
25000rpm, 60′, 4°C

pellet

“fluffy”
interface

45000rpm, 1.5 h, 4°C

resuspend in
2 ml HES/pI

resuspend in 10ml HES
18000rpm, 30′, 4°C

discard
supernatant
discard
supernatant

MN fraction

pellet
resuspend in
150µl HES/pI

PM fraction

pellet
resuspend in
200µl HES/pI

LDM fraction
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Pouring gels for Western blot
Recipes
Solution A
 40% w/v bis-acrylamide solution
Solution B
 25 ml 3M tris-HCl, pH 8.8
23 ml H2O
2 ml 10% SDS
Solution C
 25 ml 1M tris-HCl, pH 7.0
23 ml H2O
2 ml 10% SDS
10% APS
 0.5 g ammonium persulfate
5 ml H2O
1. Set up gel pouring apparatus.
2. Prepare resolving gel (normally 10%) by combining the ingredients according to the
table. This is enough to pour 2 gels. Add TEMED and APS immediately before
pouring into the gel apparatus.

Solution A (ml)
Solution B (ml)
H2O (ml)
TEMED (µl)
10% APS (µl)

6%
2.25
3.75
9.00
10
75

8%
3.00
3.75
8.25
5
75

10%
3.75
3.75
7.50
5
75

12%
4.50
3.75
6.75
5
75

14%
5.25
3.75
6.00
5
75

16%
6.00
3.75
5.25
5
75

3. Pour resolving gel into the gel apparatus and top off with a thin layer of isopropyl
alcohol.
4. Allow the resolving gel to set/solidify.
5. Prepare 4% stacking gel by combining 0.60 ml Solution A, 1.50 ml Solution C, 3.96
ml H2O, 10 µl TEMED, and 40 µl 10% APS. Add TEMED and APS immediately
before pouring into the gel apparatus.
6. Pour off the isopropyl alcohol and add stacking gel. Immediately put in the well
combs.
7. Allow the stacking gel to set/solidify.
8. Use the same day or store at 4°C wrapped in moist towels and stored in a Tupperware
container for up to 3 days.
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Western blot analysis
Recipes
1X Tris-glycine buffer
 100 ml 10X tris-glycine
900 ml nanopure water

20X TBS
 200 ml 1M tris-HCl (pH 8)
87.66 g NaCl
 fill to 1 L with nanopure water

20X transfer buffer
 116 g tris-BASE
58 g glycine
74 ml 10% SDS
 fill to 1 L with nanopure water

1X TBS
 50 ml 20X TBS
750 µl Tween-20
 fill to 1 L with nanopure water

1X transfer buffer
 50 ml 20X transfer buffer
200 ml methanol
750 ml nanopure water

1% Blocking Solution
 1 g nonfat milk
1 g BSA
100 ml 1X TBST

1.
2.
3.
4.
5.
6.
7.

Prepare protein samples.
Boil samples for 5′, place on ice briefly, and spin down before loading onto gel.
Run protein gel at 125 V for 1.5 h at RT in 1X tris-glycine buffer.
Run transfer at 100 V for 1 h surrounded with ice in 1X transfer buffer.
Shake membrane in blocking solution for 1 h at RT.
Shake membrane in 1° antibody overnight at 4°C.
Wash membrane: one quick wash followed by three 10 min washes with 1X
TBST.
8. Shake membrane with 2° antibody for 1 h at RT.
9. Wash membrane: one quick wash followed by three 10 min washes with 1X
TBST.
10. Develop membrane with ECL Western Blotting Substrate kit, using
approximately 1 ml substrate per blot (equal volumes detection reagent 1 and 2).
- Allow membrane to sit 1′.
- Blot excess substrate on paper towel.
- Cover membrane with saran wrap.
11. Develop membrane with X-ray.
12. Store membrane at 4°C.
13. To reprobe membranes:
- Shake membrane in Western stripping solution for 15′ at RT.
- Shake membrane in 1X TBST for 15′ at RT.
- Follow protocol above starting at step 6 (1° antibody).
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Western blot antibodies
1° Antibody

2° Antibody

MW

ATP10C

Sigma
(purified)

10 µl/10 ml

anti-rabbit

5 µl/10 ml

70 kDa

GLUT1

Alpha
Diagnostic
(GT11-A)

10 µl/10 ml

anti-rabbit

5 µl/10 ml

40-80 kDa

GLUT4

AbCam
(ab654)

4 µl/10 ml

anti-rabbit

5 µl/10 ml

70 kDa

Na+-K+ ATPase

Novus
Biologicals
(NB300-146)

2 µl/10 ml

anti-mouse

5 µl/10 ml

112 kDa

β-TUBULIN

Sigma
(T2200)

6 µl/10 ml

anti-rabbit

5 µl/10 ml

55 kDa
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Glucose uptake
Recipes
Krebs-Ringer HEPES (KRH) buffer
 121 mM NaCl (7.07 g), 4.9 mM KCl (0.365 g), 1.2 mM MgSO4 (0.144 g),
0.33 mM CaCl2 (0.048 g), 12 mM HEPES (2.86 g)
 dilute to 1 L with water
 pH to 7.4
 add 25 mM D-glucose (2.25 g) to 500 ml of the buffer for KRH (+) glucose
 sterile filter both KRH (-) glucose and KRH (+) glucose and store at 4°C
Digitonin release buffer
 0.25 M mannitol (22.78 g), 17 mM MOPS (1.78 g), 2.5 mM EDTA (2.5 ml of
0.5 M EDTA), 0.25 M digitonin (8 mg/ml, 0.4 g)
 dilute to 500 ml with water and pH to 7.4
 heat to 98°C to dissolve, leave on benchtop overnight to bring back to room
temperature
cold 2-deoxyglucose (2-DOG)
 add 0.13 g 2-deoxyglucose in 40 ml KRH (-) glucose
 store at -20°C
cytochalasin B
 stock (Sigma C-6762) is 1 mM in 100% ethanol
 add 5 µl cytochalasin B/1 ml cocktail
cocktail
# wells
10
20
25
30
35
40
45
50

KRH (-)
glucose
9.94 ml
19.88 ml
24.86 ml
29.82 ml
34.80 ml
39.76 ml
44.74 ml
49.70 ml

Cold 2-DOG

3

H 2-DOG

50 µl
100 µl
125 µl
150 µl
175 µl
200 µl
225 µl
250 µl

10 µl
20 µl
25 µl
30 µl
35 µl
40 µl
45 µl
50 µl

1. In the morning, wash cells with DMEM 2X
2. Serum starve cells 3-5hrs in DMEM only
3. Set-up 6-well plate as follows:
-C
-C
+C
-I

(1)

(2)

(3)

+I

(4)

(5)

(6)
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4. Add fresh DMEM with or without insulin (100 nM insulin = 0.6 µl and 1 µM
insulin = 6 µl in 10 ml DMEM) and incubate 37°, 30′
5. Wash plates twice with 1 ml of KRH (-) glucose at RT
6. Add 1 ml of "cocktail" with or without cytochalasin B per well
- “cocktail” without cytochalasin B (-C), 24 wells, 25 ml
24.85 ml KRH (-) glucose
+ 125 µl cold 2-DOG
+ 25 µl 3H 2-DOG
- “cocktail” with cytochalasin B (+C), 12 wells, 15 ml
14.9 ml KRH (-) glucose
+ 75 µl cold 2-DOG
+ 15 µl 3H 2-DOG
+ 75 µl cytochalasin B
7. Incubate at 37° for 5′ exactly
8. Terminate incorporation by aspirating off cocktail
9. Wash plate TWICE with 1ml of ice cold KRH (+) glucose
10. Add 2.2 ml of digitonin release buffer at RT to each plate; incubate 5′
11. Scrape cells and transfer to labeled (1-6) 5 ml eppendorf tube
12. Vortex to break clumps
13. Add 2 ml of the lysates to a scintillation vial with 10 ml scintillation fluid
14. Save remaining 200 µl lysate and store at –80°
15. To another scintillation vial, add 66µl of "cocktail" (without cytochalasin B),
1934 µl of digitonin release buffer, and 10 ml scintillation fluid (this tells you the
specific activity)
16. Count for 5 min in a scintillation counter
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